A Phase 1 interventional study of feladilimab (GSK3359609) and GSK3174998 in Neoplasms, sponsored by GlaxoSmithKline. Completed at 28 sites in 9 countries. Open to participants aged 18 Years to 93 Years. Per ClinicalTrials.gov, last updated 2024-12-27.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in participants with selected, advanced or recurrent solid tumors with the aim to establish recommended dose(s) of GSK3359609 for further exploration as monotherapy and in combination with pembrolizumab or chemotherapy regimens. The study is comprised of two primary parts, each composed of two phases: Part 1: GSK3359609 monotherapy with Part 1A as dose escalation phase and Part 1B as cohort expansion phase; Part 2: GSK3359609 combination therapy with Part 2A pembrolizumab or GSK3174998 or chemotherapy or pembrolizumab plus chemotherapy or dostarlimab plus cobolimab or Bintrafusp alfa combination dose escalation phase and Part 2B expansion phase with pembrolizumab. The primary objective of the study is to determine the safety, tolerability, maximum tolerated dose or the maximum administered dose of GSK3359609 alone or in combination.
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's enrollment of 829 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
• Anticancer therapy within 30 days or 5 half-lives of the drug, whichever is shorter. At least 14 days must have elapsed between the last dose of prior anticancer agent and the first dose of study drug is administered.
• Part 2B (GSK3359609/pembrolizumab combination): prior pembrolizumab washout is not required.
• Prior radiation therapy: permissible if at least one non-irradiated is available for assessment according to version 1.1 or if a solitary measurable lesion was irradiated, objective progression is documented. A wash out of at least two weeks before start of study drug for radiation of any intended use to the extremities for bone and 4 weeks for radiation to the chest, brain, or visceral organs is required. • therapy within 30 days or 5 half-lives of the investigational product (whichever is shorter). At least 14 days must have elapsed between the last dose of investigational agent and the first dose of study drug is administered.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive feladilimab (GSK3359609) administered continuously at a dose level dependent on to which dose level the participant is accrued.
Drug: feladilimab (GSK3359609)
Participants will receive feladilimab (GSK3359609) administered continuously at a dose level chosen for further exploration in dose expansion cohorts.
Drug: feladilimab (GSK3359609)
Participants will receive feladilimab (GSK3359609) administered continuously in combination with pembrolizumab.
Drug: feladilimab (GSK3359609) · Drug: Pembrolizumab
Participants will receive feladilimab (GSK3359609) administered continuously in combination with GSK3174998.
Drug: feladilimab (GSK3359609) · Drug: GSK3174998
Participants participating in Part 2A chemotherapy combination cohorts will receive feladilimab (GSK3359609) in combination with chemotherapy at doses and schedules based on standard of care practice.
Drug: feladilimab (GSK3359609) · Drug: Docetaxel · Drug: Pemetrexed · Drug: Paclitaxel plus Carboplatin · Drug: Gemcitabine plus Carboplatin · Drug: Fluorouracil (5-FU) plus carboplatin or cisplatin
Participants will receive feladilimab (GSK3359609) administered continuously in combination with pembrolizumab.
Drug: feladilimab (GSK3359609) · Drug: Pembrolizumab
Participants will receive feladilimab (GSK3359609) administered continuously in combination with dostarlimab.
Drug: feladilimab (GSK3359609) · Drug: Dostarlimab
Participants will receive feladilimab (GSK3359609) administered continuously in combination with dostarlimab followed by cobolimab.
Drug: feladilimab (GSK3359609) · Drug: Dostarlimab · Drug: Cobolimab
Participants will receive feladilimab (GSK3359609) administered continuously in combination with bintrafusp alfa.
Drug: feladilimab (GSK3359609) · Drug: Bintrafusp alfa
Drug pages: Paclitaxel · Carboplatin
Drug pages: Gemcitabine · Carboplatin
Drug page: Fluorouracil
Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the Medical Dictionary for Regulatory Affairs (MedDRA dictionary).
Time frame: Up to approximately 367 weeks
Part 1A: Number of Participants With Dose Limiting Toxicity (DLT)
DLT is an AE that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 28-day DLT period and meets at least one of the DLT criteria: Febrile neutropenia; Grade 4 neutropenia of \>7 days in duration or requiring Granulocyte Colony-stimulating Factor (G-CSF), anemia, thrombocytopenia, non-hematologic toxicity; Grade 3 thrombocytopenia with bleeding, pneumonitis, toxicity that does not resolve to Grade 1 or baseline within 3 days; Grade 2 ocular toxicity; Toxicity that results in permanent discontinuation of feladilimab during the first four weeks of treatment; any other event which in the judgment of the investigator and GSK Medical Monitor is considered to be a DLT.
Time frame: Up to 28 days
Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.
Time frame: Baseline (Day 1) and up to approximately 367 weeks
Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
Normal ranges were 0.1 to 0.3 micromoles (umol)/liter (L) (direct bilirubin); 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
Time frame: Up to approximately 367 weeks
Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.
Time frame: Baseline (Day 1) and up to approximately 367 weeks
Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells /L (eosinophils), 41 to 50 percentage of red blood cells (RBC) in blood (hematocrit), 1,000 - 4,800 lymphocytes per microliter (µL) of blood (lymphocytes), 80-100 femtoliters (fl) (erythrocytes, mean corpuscular volume), 2 to 8 percentage of WBC (monocytes), 40 to 60 cells/mcL (neutrophils) and Women: 4.2 to 5.4 million RBC/ microliter (mcL) of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
Time frame: Up to approximately 367 weeks
Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.
Time frame: Up to approximately 367 weeks
Part 1A: Number of Participants With Dose Modifications of Feladilimab
Number of participants with dose modifications (including dose delays, dose escalations and infusion interruptions) were reported for Feladilimab.
Time frame: Up to approximately 367 weeks
Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or Is a congenital anomaly/birth defect, Other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the MedDRA dictionary.
Time frame: Up to approximately 367 weeks
Part 2A: Number of Participants With Dose Limiting Toxicity (DLT)
DLT is an AE that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 28-day DLT period and meets at least one of the DLT criteria: Febrile neutropenia; Grade 4 neutropenia of \>7 days in duration or requiring Granulocyte Colony-stimulating Factor (G-CSF), anemia, thrombocytopenia, non-hematologic toxicity; Grade 3 thrombocytopenia with bleeding, pneumonitis, toxicity that does not resolve to Grade 1 or baseline within 3 days; Grade 2 ocular toxicity; Toxicity that results in permanent discontinuation of feladilimab monotherapy or in combination during the first four weeks of treatment; any other event which in the judgment of the investigator and GSK Medical Monitor is considered to be a DLT.
Time frame: Up to 28 days
Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.
Time frame: Baseline (Day 1) and up to approximately 367 weeks
Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
Normal ranges were 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
Time frame: Up to approximately 367 weeks
Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.
Time frame: Baseline (Day 1) and up to approximately 367 weeks
Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells /L (eosinophils), 41 to 50 percentage of RBC in blood (hematocrit), 2 to 8 percentage of WBC (monocytes), 40 to 60 cells/mcL (neutrophils) and Women: 4.2 to 5.4 million RBC/mcL of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
Time frame: Up to approximately 367 weeks
Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.
Time frame: Up to approximately 367 weeks
Part 2A: Number of Participants With Dose Modifications of Feladilimab
Number of participants with dose modifications (including dose delays, dose escalations, and infusion interruptions) were reported for Feladilimab
Time frame: Up to approximately 367 weeks
Part 1B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or Is a congenital anomaly/birth defect, Other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the MedDRA dictionary.
Time frame: Up to approximately 367 weeks
Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.
Time frame: Baseline (Day 1) and up to approximately 367 weeks
Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
Normal ranges were 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%
Time frame: Up to approximately 367 weeks
Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.
Time frame: Baseline (Day 1) and up to approximately 367 weeks
Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells /L (eosinophils), 41 to 50 percentage of RBC in blood (hematocrit), 2 to 8 percentage of WBC (monocytes), and Women: 4.2 to 5.4 million RBC/ mcL of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocyte count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
Time frame: Up to approximately 367 weeks
Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.
Time frame: Up to approximately 367 weeks
Part 1B: Number of Participants With Dose Modifications of Feladilimab
Number of participants with dose modifications (including dose delays, dose escalation and infusion interruptions) were reported for Feladilimab.
Time frame: Up to approximately 367 weeks
Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the MedDRA dictionary.
Time frame: Up to approximately 367 weeks
Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.
Time frame: Baseline (Day 1) and up to approximately 367 weeks
Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
Normal ranges were 0.1 to 0.3 micromoles (umol)/liter (L) (direct bilirubin); 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); 24-204 ug/L (creatine kinase); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
Time frame: Up to approximately 367 weeks
Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.
Time frame: Baseline (Day 1) and up to approximately 367 weeks
Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells/L(eosinophils), 41 to 50 percentage of RBC in blood (hematocrit), 1,000 - 4,800 lymphocytes per microliter (µL) of blood (lymphocytes), 80-100 fl (erythrocytes, mean corpuscular volume), 2 to 8 percentage of WBC (monocytes), 40 to 60 cells/mcL (neutrophils) and Women: 4.2 to 5.4 million RBC/ mcL of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
Time frame: Up to approximately 367 weeks
Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.
Time frame: Up to approximately 367 weeks
Part 2B: Number of Participants With Dose Modifications of Feladilimab
Number of participants with dose modifications (including dose delays, dose escalations, and infusion interruptions) were reported for Feladilimab.
Time frame: Up to approximately 367 weeks
Part 1A: Overall Response Rate (ORR)
ORR was defined as the percentage of participants with immune-related confirmed complete response (irCR) or ir confirmed partial response (irPR) per Immune-related Response Evaluation Criteria in Solid Tumors Criteria (irRECIST). irCR is defined as disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to approximately 367 weeks
Part 1A: Disease Control Rate (DCR)
DCR was defined as percentage of participants with best overall response of irCR or irPR at any time + ir stable disease (irSD) meeting the minimum time criteria from the start of treatment until ir disease progression (irPD) or death due to any cause or the start of new anticancer therapy/crossover. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. irPR defined as at least 30% decrease in the sum of diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. IrPD defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.
Time frame: Up to approximately 367 weeks
Part 1A: Overall Survival (OS)
OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.
Time frame: Up to approximately 367 weeks
Part 1A: Progression-free Survival (PFS)
PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1
Time frame: Up to approximately 367 weeks
Part 1A: Time to Overall Response (TTR)
TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to approximately 367 weeks
Part 1A: Duration of Response (DOR)
DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.
Time frame: Up to approximately 367 weeks
Part 2A: Overall Response Rate (ORR)
ORR was defined as the percentage of participants with irCR or irPR per irRECIST. irCR is defined as disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to approximately 367 weeks
Part 2A: Disease Control Rate (DCR)
DCR was defined as percentage of participants with best overall response of irCR or irPR at any time + irSD meeting the minimum time criteria from the start of treatment until irPD or death due to any cause or the start of new anticancer therapy/crossover. irCR defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. irPR defined as at least 30% decrease in the sum of diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. IrPD defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.
Time frame: Up to approximately 367 weeks
Part 2A: Overall Survival (OS)
OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.
Time frame: Up to approximately 367 weeks
Part 2A: Progression-free Survival (PFS)
PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease Progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.
Time frame: Up to approximately 367 weeks
Part 2A: Time to Overall Response (TTR)
TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to approximately 367 weeks
Part 2A: Duration of Response (DOR)
DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression is defined as the date of radiological disease progression based on imaging data per RECIST v1.1.
Time frame: Up to approximately 367 weeks
Part 1B: Overall Response Rate (ORR)
ORR was defined as the percentage of participants with a confirmed irCR or confirmed irPR per irRECIST. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to approximately 367 weeks
Part 1B: Disease Control Rate (DCR)
DCR was defined as percentage of participants with best overall response of irCR or irPR at any time + irSD meeting the minimum time criteria from the start of treatment until irPD or death due to any cause or the start of new anticancer therapy/crossover. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. irPR defined as at least 30% decrease in the sum of diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. IrPD defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.
Time frame: Up to approximately 367 weeks
Part 1B: Overall Survival (OS)
OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.
Time frame: Up to approximately 367 weeks
Part 1B: Progression-free Survival (PFS)
PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.
Time frame: Up to approximately 367 weeks
Part 1B: Time to Overall Response (TTR)
TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to approximately 367 weeks
Part 1B: Duration of Response (DOR)
DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression is defined as the date of radiological disease progression based on imaging data per RECIST v1.1.
Time frame: Up to approximately 367 weeks
Part 2B: Overall Response Rate (ORR)
ORR was defined as the percentage of participants with a confirmed irCR or confirmed irPR per irRECIST. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to approximately 367 weeks
Part 2B: Disease Control Rate (DCR)
DCR was defined as the percentage of participants with a best overall response of irCR or irPR at any time plus irSD meeting the minimum time criteria from the start of treatment until irPD or death due to any cause or the start of new anticancer therapy/crossover. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. irPD is defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.
Time frame: Up to approximately 367 weeks
Part 2B: Overall Survival (OS)
OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.
Time frame: Up to approximately 367 weeks
Part 2B: Progression-free Survival (PFS)
PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.
Time frame: Up to approximately 367 weeks
Part 2B: Time to Overall Response (TTR)
TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to approximately 367 weeks
Part 2B: Duration of Response (DOR)
DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression is defined as the date of radiological disease progression based on imaging data per RECIST v1.1
Time frame: Up to approximately 367 weeks
Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab
Blood samples were collected for Pharmacokinetic (PK) analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours POST EOI; week 1; week 2; Pre-dose and 0.5 hours POST EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours POST EOI in week 6, 9, 12 15; Pre-dose in week 21 and 33
Part 1A: Area Under the Concentration-time Curve From Time 0 to 504 Hours After Dosing [AUC (0-504h)] of Feladilimab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours post-EOI in week 6, 9, 12 15; Pre-dose in week 21 and 33
Part 2A: Ctau of Pembrolizumab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93
Part 2A: AUC (0-504h) of Pembrolizumab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93
Part 2A: Cmax and Ctau of GSK3174998
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93
Part 2A: AUC (0-504 h) of GSK3174998
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93
Part 1B: Cmax and Ctau of Feladilimab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours post-EOI in week 6, 9, 12 15; Pre-dose in week 21, 33 and 45
Part 1B: AUC (0-504 h) of Feladilimab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours post-EOI in week 6, 9, 12 15; Pre-dose in week 21, 33 and 45
Part 2B: Cmax and Ctau of Feladilimab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93
Part 2B: AUC (0-504 h) of Feladilimab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93
Part 2B: AUC (0-1008 h) of Feladilimab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93
Part 2B: Cmax and Ctau of Pembrolizumab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93
Part 2B: AUC (0-504h) of Pembrolizumab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93
Part 1A: Number of Participants With Positive Results in Anti-drug Antibody (ADA) Test by Feladilimab Dose Level
Serum samples collected and tested for the presence of ADA with a screening assay.
Time frame: Up to approximately 367 weeks
Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab in Combination With GSK3174998 Dose Level
Serum samples collected and tested for the presence of ADA with a screening assay.
Time frame: Up to approximately 367 weeks
Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level in Combination With Pembrolizumab
Serum samples collected and tested for the presence of ADA with a screening assay.
Time frame: Up to approximately 367 weeks
Part 2A: Number of Participants With Positive Results in ADA in Pembrolizumab
Serum samples collected and tested for the presence of ADA with a screening assay.
Time frame: Up to approximately 367 weeks
Part 2A: Number of Participants With Positive Results in ADA in GSK3174998
Serum samples collected and tested for the presence of ADA with a screening assay.
Time frame: Up to approximately 367 weeks
Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Combination With Chemotherapies Dose Level
Serum samples collected and tested for the presence of ADA with a screening assay.
Time frame: Up to approximately 367 weeks
Part 1B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level
Serum samples collected and tested for the presence of ADA with a screening assay.
Time frame: Up to approximately 367 weeks
Part 2B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level
Serum samples collected and tested for the presence of ADA with a screening assay.
Time frame: Up to approximately 367 weeks
Part 2B: Number of Participants With Positive Results in ADA in Pembrolizumab
Serum samples collected and tested for the presence of ADA with a screening assay.
Time frame: Up to approximately 367 weeks
Part 1A: Receptor Occupancy of Feladilimab
Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.
Time frame: Up to approximately 367 weeks
Part 2A: Receptor Occupancy of Feladilimab
Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.
Time frame: Up to approximately 367 weeks
Part 1B: Receptor Occupancy of Feladilimab
Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.
Time frame: Up to approximately 367 weeks
Part 2B: Receptor Occupancy of Feladilimab
Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.
Time frame: Up to approximately 367 weeks
| Milestone | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg | Crossover: Fela 0.100 mg/kg + Pembro 200 mg | Crossover: Fela 0.300 mg/kg + Pembro 200 mg | Crossover: Fela 1.000 mg/kg + Pembro 200 mg | Crossover: Fela 3.000 mg/kg + Pembro 200 mg | Crossover: Fela 24 mg + Pembro 200 mg | Crossover: Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 2 | 7 | 24 | 25 | 15 | 27 | 7 | 0 | 0 | 0 | 5 | 5 | 5 | 8 | 11 | 11 | 1 | 4 | 16 | 4 | 3 | 6 | 36 | 13 | 22 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 1 | 2 | 7 | 24 | 24 | 15 | 27 | 7 | 0 | 0 | 0 | 4 | 4 | 5 | 7 | 8 | 11 | 1 | 4 | 16 | 4 | 2 | 6 | 35 | 10 | 21 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 1 | 2 | 7 | 18 | 17 | 11 | 21 | 3 | 0 | 0 | 0 | 2 | 4 | 5 | 6 | 6 | 7 | 1 | 3 | 13 | 3 | 2 | 4 | 31 | 7 | 13 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Participants were crossed over or were re-treated following progression | 0 | 0 | 0 | 0 | 5 | 2 | 2 | 4 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Site closed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 1 | 3 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg | Crossover: Fela 0.100 mg/kg + Pembro 200 mg | Crossover: Fela 0.300 mg/kg + Pembro 200 mg | Crossover: Fela 1.000 mg/kg + Pembro 200 mg | Crossover: Fela 3.000 mg/kg + Pembro 200 mg | Crossover: Fela 24 mg + Pembro 200 mg | Crossover: Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39 | 115 | 59 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 255 | 44 | 23 | 4 | 6 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 14 | 2 | 3 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 38 | 112 | 56 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 241 | 42 | 20 | 4 | 3 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 69 | 48 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 202 | 31 | 17 | 2 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 19 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Participants were crossed over or were re-treated following progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 36 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Site closed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 4 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg | Crossover: Fela 0.100 mg/kg + Pembro 200 mg | Crossover: Fela 0.300 mg/kg + Pembro 200 mg | Crossover: Fela 1.000 mg/kg + Pembro 200 mg | Crossover: Fela 3.000 mg/kg + Pembro 200 mg | Crossover: Fela 24 mg + Pembro 200 mg | Crossover: Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 19 | 42 | 2 | 1 | 1 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 19 | 39 | 2 | 1 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 14 | 32 | 2 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
| Withdrew: Site closed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the Medical Dictionary for Regulatory Affairs (MedDRA dictionary).
| Participants | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Any AEs | 1 | 1 | 2 | 7 | 22 | 24 | 13 | 21 | 6 |
| Any SAEs | 0 | 0 | 1 | 2 | 6 | 8 | 4 | 12 | 1 |
DLT is an AE that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 28-day DLT period and meets at least one of the DLT criteria: Febrile neutropenia; Grade 4 neutropenia of \>7 days in duration or requiring Granulocyte Colony-stimulating Factor (G-CSF), anemia, thrombocytopenia, non-hematologic toxicity; Grade 3 thrombocytopenia with bleeding, pneumonitis, toxicity that does not resolve to Grade 1 or baseline within 3 days; Grade 2 ocular toxicity; Toxicity that results in permanent discontinuation of feladilimab during the first four weeks of treatment; any other event which in the judgment of the investigator and GSK Medical Monitor is considered to be a DLT.
| Participants | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Part 1A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.
| Participants | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Hypoglycemia , Grade 0, Grade 1 | 0 | 0 | 0 | 0 | 1 | 4 | 1 | 1 | 0 |
| Hypoglycemia , Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Hypoglycemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 0, Grade 1 | 0 | 1 | 0 | 1 | 10 | 5 | 7 | 11 | 1 |
| Hyperglycemia , Grade 0, Grade 2 | 0 | 0 | 0 | 2 | 1 | 3 | 2 | 1 | 0 |
| Hyperglycemia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyperglycemia , Grade 1, Grade 2 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 |
| Hyperglycemia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hyperglycemia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hyperglycemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 0, Grade 1 | 1 | 0 | 1 | 3 | 6 | 5 | 6 | 9 | 1 |
| Hypoalbuminemia , Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 6 | 1 | 1 | 0 | 1 |
| Hypoalbuminemia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 1 | 0 |
| Hypoalbuminemia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 0, Grade 1 | 0 | 0 | 0 | 2 | 4 | 6 | 4 | 3 | 2 |
| AP Increased, Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| AP Increased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| AP Increased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 |
| AP Increased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| AP Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 2, Grade 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| AP Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 0, Grade 1 | 0 | 0 | 0 | 1 | 3 | 0 | 3 | 5 | 0 |
| ALT Increased, Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| ALT Increased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| ALT Increased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| ALT Increased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| ALT Increased, Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 0, Grade 1 | 0 | 0 | 0 | 2 | 5 | 4 | 3 | 9 | 1 |
| AST Increased, Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 |
| AST Increased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| AST Increased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| AST Increased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| AST Increased, Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| AST Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 0, Grade 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 |
| Blood Bilirubin Increased, Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| Blood Bilirubin Increased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Blood Bilirubin Increased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Blood Bilirubin Increased, Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 0, Grade 1 | 0 | 0 | 0 | 1 | 6 | 2 | 2 | 2 | 4 |
| Creatinine Increased, Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Creatinine Increased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 0, Grade 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 4 | 0 |
| Hypokalemia , Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Missing, Grade 0 | — | — | — | — | 1 | — | — | — | — |
| Hypokalemia , Missing, Grade 1 | — | — | — | — | 0 | — | — | — | — |
| Hypokalemia , Missing, Grade 2 | — | — | — | — | 0 | — | — | — | — |
| Hypokalemia , Missing, Grade 3 | — | — | — | — | 0 | — | — | — | — |
| Hypokalemia , Missing, Grade 4 | — | — | — | — | 0 | — | — | — | — |
| Hyperkalemia , Grade 0, Grade 1 | 0 | 1 | 0 | 2 | 5 | 7 | 4 | 6 | 1 |
| Hyperkalemia , Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Hyperkalemia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Hyperkalemia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Missing, Grade 0 | — | — | — | — | 1 | — | — | — | — |
| Hyperkalemia , Missing, Grade 1 | — | — | — | — | 0 | — | — | — | — |
| Hyperkalemia , Missing, Grade 2 | — | — | — | — | 0 | — | — | — | — |
| Hyperkalemia , Missing, Grade 3 | — | — | — | — | 0 | — | — | — | — |
| Hyperkalemia , Missing, Grade 4 | — | — | — | — | 0 | — | — | — | — |
| Hyponatremia , Grade 0, Grade 1 | 0 | 0 | 1 | 3 | 3 | 7 | 3 | 3 | 0 |
| Hyponatremia , Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
| Hyponatremia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 0, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Hypernatremia , Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypernatremia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 0, Grade 1 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 3 | 0 |
| Hypocalcemia , Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hypocalcemia , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Hypocalcemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Missing, Grade 0 | — | — | — | — | 1 | — | — | — | — |
| Hypocalcemia , Missing, Grade 1 | — | — | — | — | 0 | — | — | — | — |
| Hypocalcemia , Missing, Grade 2 | — | — | — | — | 0 | — | — | — | — |
| Hypocalcemia , Missing, Grade 3 | — | — | — | — | 0 | — | — | — | — |
| Hypocalcemia , Missing, Grade 4 | — | — | — | — | 0 | — | — | — | — |
| Hypercalcemia , Grade 0, Grade 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hypercalcemia , Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypercalcemia , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Hypercalcemia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Missing, Grade 0 | — | — | — | — | 0 | — | — | — | — |
| Hypercalcemia , Missing, Grade 1 | — | — | — | — | 1 | — | — | — | — |
| Hypercalcemia , Missing, Grade 2 | — | — | — | — | 0 | — | — | — | — |
| Hypercalcemia , Missing, Grade 3 | — | — | — | — | 0 | — | — | — | — |
| Hypercalcemia , Missing, Grade 4 | — | — | — | — | 0 | — | — | — | — |
| Chronic Kidney Disease , Grade 0, Grade 1 | — | — | — | 0 | 1 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 0, Grade 2 | — | — | — | 0 | 0 | 0 | 1 | 0 | 0 |
| Chronic Kidney Disease , Grade 0, Grade 3 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 0, Grade 4 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 1, Grade 0 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 1, Grade 2 | — | — | — | 1 | 3 | 0 | 0 | 0 | 1 |
| Chronic Kidney Disease , Grade 1, Grade 3 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 1, Grade 4 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 2, Grade 0 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 2, Grade 1 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 2, Grade 3 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 2, Grade 4 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 3, Grade 0 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 3, Grade 1 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 3, Grade 2 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 3, Grade 4 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 4, Grade 0 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 4, Grade 1 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 4, Grade 2 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 4, Grade 3 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Missing, Grade 0 | — | — | — | — | 0 | 1 | — | 1 | — |
| Chronic Kidney Disease , Missing, Grade 1 | — | — | — | — | 1 | 1 | — | 0 | — |
| Chronic Kidney Disease , Missing, Grade 2 | — | — | — | — | 0 | 0 | — | 1 | — |
| Chronic Kidney Disease , Missing, Grade 3 | — | — | — | — | 0 | 0 | — | 0 | — |
| Chronic Kidney Disease , Missing, Grade 4 | — | — | — | — | 0 | 1 | — | 0 | — |
Normal ranges were 0.1 to 0.3 micromoles (umol)/liter (L) (direct bilirubin); 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
| Participants | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Direct Bilirubin (umol/L), To Low | — | — | — | — | 0 | — | — | — | — |
| Direct Bilirubin (umol/L), To Normal or No Change | — | — | — | — | 0 | — | — | — | — |
| Direct Bilirubin (umol/L), To High | — | — | — | — | 1 | — | — | — | — |
| Lactate Dehydrogenase (IU/L), To Low | — | — | — | — | 0 | 0 | 0 | — | — |
| Lactate Dehydrogenase (IU/L), To Normal or No Change | — | — | — | — | 0 | 0 | 0 | — | — |
| Lactate Dehydrogenase (IU/L), To High | — | — | — | — | 1 | 2 | 1 | — | — |
| Protein (g/L), To Low | 0 | 0 | 0 | 2 | 6 | 7 | 1 | 3 | 1 |
| Protein (g/L), To Normal or No Change | 1 | 1 | 2 | 5 | 18 | 15 | 9 | 21 | 5 |
| Protein (g/L), To High | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 4 | 1 |
| Triiodothyronine, Free (pmol/L), To Low | 0 | 0 | 0 | 3 | 5 | 6 | 2 | 2 | 1 |
| Triiodothyronine, Free (pmol/L), To Normal or No Change | 1 | 1 | 0 | 4 | 12 | 16 | 8 | 21 | 5 |
| Triiodothyronine, Free (pmol/L), To High | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 0 | 1 |
| Thyroxine, Free (pmol/L), To Low | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Thyroxine, Free (pmol/L), To Normal or No Change | 1 | 1 | 1 | 6 | 19 | 21 | 10 | 22 | 5 |
| Thyroxine, Free (pmol/L), To High | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 1 |
| Troponin I (ug/L), To Low | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Troponin I (ug/L), To Normal or No Change | 1 | — | 1 | 3 | 6 | 10 | 1 | 8 | 2 |
| Troponin I (ug/L), To High | 0 | — | 0 | 1 | 2 | 0 | 1 | 0 | 1 |
| Troponin T (ug/L), To Low | — | — | — | — | 0 | 0 | 0 | 0 | 0 |
| Troponin T (ug/L), To Normal or No Change | — | — | — | — | 8 | 8 | 8 | 10 | 2 |
| Troponin T (ug/L), To High | — | — | — | — | 3 | 0 | 1 | 3 | 0 |
| Thyrotropin (mU/L), To Low | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Thyrotropin (mU/L), To Normal or No Change | 1 | 1 | 1 | 5 | 18 | 21 | 10 | 20 | 7 |
| Thyrotropin (mU/L), To High | 0 | 0 | 0 | 2 | 1 | 2 | 0 | 2 | 0 |
| Urea (mmol/L), To Low | 0 | 0 | 0 | 0 | 1 | 3 | 2 | 0 | 0 |
| Urea (mmol/L), To Normal or No Change | 1 | 0 | 1 | 3 | 12 | 11 | 7 | 15 | 2 |
| Urea (mmol/L), To High | 0 | 1 | 1 | 3 | 6 | 6 | 3 | 6 | 3 |
Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.
| Participants | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Anemia , Grade 0, Grade 1 | 1 | 0 | 0 | 3 | 8 | 1 | 2 | 6 | 1 |
| Anemia , Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Anemia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Anemia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 1, Grade 2 | 0 | 0 | 1 | 1 | 4 | 5 | 2 | 3 | 2 |
| Anemia , Grade 1, Grade 3 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 |
| Anemia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 0 |
| Anemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 0, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hemoglobin Increased, Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 0, Grade 1 | 1 | 0 | 0 | 1 | 5 | 5 | 2 | 6 | 3 |
| Lymphocyte Count Decreased, Grade 0, Grade 2 | 0 | 0 | 0 | 1 | 3 | 3 | 2 | 2 | 0 |
| Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 0 |
| Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 1, Grade 2 | 0 | 0 | 1 | 0 | 5 | 2 | 1 | 1 | 1 |
| Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 0 |
| Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 0 |
| Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Missing, Grade 0 | — | — | — | — | 0 | — | — | — | — |
| Lymphocyte Count Decreased, Missing, Grade 1 | — | — | — | — | 0 | — | — | — | — |
| Lymphocyte Count Decreased, Missing, Grade 2 | — | — | — | — | 0 | — | — | — | — |
| Lymphocyte Count Decreased, Missing, Grade 3 | — | — | — | — | 1 | — | — | — | — |
| Lymphocyte Count Decreased, Missing, Grade 4 | — | — | — | — | 0 | — | — | — | — |
| Lymphocyte Count Increased, Grade 0, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 0 |
| Lymphocyte Count Increased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Missing, Grade 0 | — | — | — | — | 1 | — | — | — | — |
| Lymphocyte Count Increased, Missing, Grade 1 | — | — | — | — | 0 | — | — | — | — |
| Lymphocyte Count Increased, Missing, Grade 2 | — | — | — | — | 0 | — | — | — | — |
| Lymphocyte Count Increased, Missing, Grade 3 | — | — | — | — | 0 | — | — | — | — |
| Lymphocyte Count Increased, Missing, Grade 4 | — | — | — | — | 0 | — | — | — | — |
| Neutrophil Count Decreased, Grade 0, Grade 1 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 1 |
| Neutrophil Count Decreased, Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Neutrophil Count Decreased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Neutrophil Count Decreased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Missing, Grade 0 | — | — | — | — | 1 | — | — | — | — |
| Neutrophil Count Decreased, Missing, Grade 1 | — | — | — | — | 0 | — | — | — | — |
| Neutrophil Count Decreased, Missing, Grade 2 | — | — | — | — | 0 | — | — | — | — |
| Neutrophil Count Decreased, Missing, Grade 3 | — | — | — | — | 0 | — | — | — | — |
| Neutrophil Count Decreased, Missing, Grade 4 | — | — | — | — | 0 | — | — | — | — |
| Platelet Count Decreased, Grade 0, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Platelet Count Decreased, Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 1, Grade 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 0, Grade 1 | 0 | 1 | 1 | 1 | 3 | 4 | 1 | 1 | 2 |
| White Blood Cell Decreased, Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| White Blood Cell Decreased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| White Blood Cell Decreased, Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 0, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells /L (eosinophils), 41 to 50 percentage of red blood cells (RBC) in blood (hematocrit), 1,000 - 4,800 lymphocytes per microliter (µL) of blood (lymphocytes), 80-100 femtoliters (fl) (erythrocytes, mean corpuscular volume), 2 to 8 percentage of WBC (monocytes), 40 to 60 cells/mcL (neutrophils) and Women: 4.2 to 5.4 million RBC/ microliter (mcL) of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
| Participants | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Basophils, To Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basophils, To Normal or No Change | 1 | 1 | 2 | 6 | 24 | 24 | 11 | 22 | 7 |
| Basophils, To High | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Eosinophils, To Low | 0 | 1 | 0 | 0 | 3 | 2 | 2 | 2 | 1 |
| Eosinophils, To Normal or No Change | 1 | 0 | 2 | 7 | 20 | 20 | 10 | 21 | 6 |
| Eosinophils, To High | 0 | 0 | 0 | 0 | 3 | 4 | 1 | 5 | 0 |
| Hematocrit, To Low | 0 | 0 | 1 | 2 | 10 | 7 | 2 | 6 | 2 |
| Hematocrit, To Normal or No Change | 1 | 1 | 1 | 5 | 14 | 18 | 13 | 21 | 5 |
| Hematocrit, To High | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Lymphocytes, To Low | — | — | — | — | 2 | 1 | 1 | — | — |
| Lymphocytes, To Normal or No Change | — | — | — | — | 0 | 0 | 0 | — | — |
| Lymphocytes, To High | — | — | — | — | 0 | 0 | 0 | — | — |
| Erythrocytes, Mean Corpuscular Volume, To Low | — | — | — | — | — | — | 1 | — | — |
| Erythrocytes, Mean Corpuscular Volume, To Normal or No Change | — | — | — | — | — | — | 0 | — | — |
| Erythrocytes, Mean Corpuscular Volume, To High | — | — | — | — | — | — | 0 | — | — |
| Monocytes, To Low | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Monocytes, To Normal or No Change | 0 | 1 | 1 | 5 | 18 | 21 | 11 | 21 | 6 |
| Monocytes, To High | 1 | 0 | 1 | 2 | 5 | 3 | 3 | 6 | 1 |
| Neutrophils, To Low | — | — | — | — | 0 | 0 | 0 | — | — |
| Neutrophils, To Normal or No Change | — | — | — | — | 0 | 0 | 0 | — | — |
| Neutrophils, To High | — | — | — | — | 1 | 1 | 1 | — | — |
| Erythrocytes, To Low | 0 | 0 | 1 | 0 | 7 | 7 | 0 | 3 | 3 |
| Erythrocytes, To Normal or No Change | 1 | 1 | 1 | 7 | 17 | 18 | 14 | 24 | 3 |
| Erythrocytes, To High | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.
| Participants | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Glucose, No Change/Decreased | 1 | 1 | 2 | 7 | 23 | 22 | 12 | 25 | 7 |
| Glucose, any increase | 0 | 0 | 0 | 0 | 1 | 3 | 2 | 2 | 0 |
| Ketones, No Change/Decreased | 0 | 0 | 1 | 6 | 19 | 21 | 10 | 15 | 5 |
| Ketones, any increase | 1 | 1 | 1 | 1 | 4 | 4 | 4 | 12 | 2 |
| Occult Blood, No Change/Decreased | 1 | 1 | 1 | 5 | 17 | 18 | 8 | 15 | 7 |
| Occult Blood, any increase | 0 | 0 | 1 | 2 | 6 | 7 | 6 | 12 | 0 |
Number of participants with dose modifications (including dose delays, dose escalations and infusion interruptions) were reported for Feladilimab.
| Participants | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Dose Delays | 0 | 0 | 0 | 1 | 2 | 1 | 2 | 3 | 1 |
| Dose Escalations | 0 | 0 | 0 | 2 | 3 | 1 | 1 | 0 | 0 |
| infusion interruptions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or Is a congenital anomaly/birth defect, Other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the MedDRA dictionary.
| Participants | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any AEs | 5 | 5 | 5 | 5 | 8 | 10 | 0 | 4 | 15 | 4 | 3 | 6 | 36 | 13 | 22 | 1 | 4 |
| Any SAEs | 3 | 2 | 3 | 2 | 3 | 4 | 0 | 2 | 5 | 2 | 1 | 4 | 13 | 3 | 17 | 0 | 1 |
DLT is an AE that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 28-day DLT period and meets at least one of the DLT criteria: Febrile neutropenia; Grade 4 neutropenia of \>7 days in duration or requiring Granulocyte Colony-stimulating Factor (G-CSF), anemia, thrombocytopenia, non-hematologic toxicity; Grade 3 thrombocytopenia with bleeding, pneumonitis, toxicity that does not resolve to Grade 1 or baseline within 3 days; Grade 2 ocular toxicity; Toxicity that results in permanent discontinuation of feladilimab monotherapy or in combination during the first four weeks of treatment; any other event which in the judgment of the investigator and GSK Medical Monitor is considered to be a DLT.
| Participants | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 2A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 3 | — | — |
Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.
| Participants | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hypoglycemia , Grade 0, Grade 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 1 | 0 | 0 | 5 | 1 | 1 | 0 | 0 |
| Hypoglycemia , Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| Hypoglycemia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 0, Grade 1 | 0 | 3 | 2 | 5 | 3 | 4 | 0 | 0 | 4 | 0 | 0 | 1 | 12 | 5 | 9 | 0 | 3 |
| Hyperglycemia , Grade 0, Grade 2 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 2 | 1 | 0 | 1 | 4 | 2 | 1 | 0 | 0 |
| Hyperglycemia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Hyperglycemia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 1, Grade 2 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 2 | 1 | 0 | 0 |
| Hyperglycemia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Hyperglycemia , Grade 1, Grade 4 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Hyperglycemia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyperglycemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyperglycemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 0, Grade 1 | 2 | 1 | 1 | 1 | 3 | 3 | 0 | 0 | 2 | 0 | 0 | 1 | 5 | 5 | 6 | 0 | 0 |
| Hypoalbuminemia , Grade 0, Grade 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 5 | 1 | 3 | 0 | 0 |
| Hypoalbuminemia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 1, Grade 2 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 3 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Missing, Grade 0 | — | — | — | — | — | — | — | — | — | — | — | — | 0 | — | — | — | — |
| Hypoalbuminemia , Missing, Grade 1 | — | — | — | — | — | — | — | — | — | — | — | — | 1 | — | — | — | — |
| Hypoalbuminemia , Missing, Grade 2 | — | — | — | — | — | — | — | — | — | — | — | — | 0 | — | — | — | — |
| Hypoalbuminemia , Missing, Grade 3 | — | — | — | — | — | — | — | — | — | — | — | — | 0 | — | — | — | — |
| Hypoalbuminemia , Missing, Grade 4 | — | — | — | — | — | — | — | — | — | — | — | — | 0 | — | — | — | — |
| AP Increased, Grade 0, Grade 1 | 1 | 0 | 2 | 3 | 3 | 2 | 1 | 0 | 6 | 0 | 1 | 1 | 7 | 3 | 6 | 0 | 1 |
| AP Increased, Grade 0, Grade 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| AP Increased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 1, Grade 2 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| AP Increased, Grade 1, Grade 3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 0, Grade 1 | 0 | 0 | 1 | 2 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 2 | 10 | 5 | 7 | 0 | 0 |
| ALT Increased, Grade 0, Grade 2 | 0 | 0 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| ALT Increased, Grade 0, Grade 3 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| ALT Increased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| ALT Increased, Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 0, Grade 1 | 0 | 1 | 3 | 5 | 2 | 6 | 0 | 0 | 1 | 1 | 0 | 0 | 9 | 2 | 5 | 0 | 2 |
| AST Increased, Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| AST Increased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| AST Increased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| AST Increased, Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 1, Grade 3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 0, Grade 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 2 | 1 | 2 | 0 | 0 |
| Blood Bilirubin Increased, Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 0, Grade 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Blood Bilirubin Increased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 0, Grade 1 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 1 | 2 | 2 | 2 | 0 | 0 |
| Creatinine Increased, Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 0 |
| Creatinine Increased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Missing, Grade 0 | — | — | — | — | — | — | — | — | — | — | — | — | 1 | — | 0 | — | — |
| Creatinine Increased, Missing, Grade 1 | — | — | — | — | — | — | — | — | — | — | — | — | 0 | — | 0 | — | — |
| Creatinine Increased, Missing, Grade 2 | — | — | — | — | — | — | — | — | — | — | — | — | 0 | — | 0 | — | — |
| Creatinine Increased, Missing, Grade 3 | — | — | — | — | — | — | — | — | — | — | — | — | 0 | — | 0 | — | — |
| Creatinine Increased, Missing, Grade 4 | — | — | — | — | — | — | — | — | — | — | — | — | 0 | — | 1 | — | — |
| Hypokalemia , Grade 0, Grade 1 | 1 | 1 | 0 | 1 | 1 | 2 | 0 | 0 | 1 | 0 | 0 | 2 | 4 | 5 | 3 | 0 | 0 |
| Hypokalemia , Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 0 | 0 |
| Hypokalemia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Hypokalemia , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Hypokalemia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 0, Grade 1 | 0 | 1 | 1 | 2 | 2 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 6 | 4 | 3 | 0 | 0 |
| Hyperkalemia , Grade 0, Grade 2 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hyperkalemia , Grade 1, Grade 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 0, Grade 1 | 1 | 0 | 2 | 2 | 5 | 6 | 0 | 2 | 1 | 2 | 0 | 2 | 8 | 9 | 12 | 0 | 1 |
| Hyponatremia , Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 1 | 1 | 0 | 0 |
| Hyponatremia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 1, Grade 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Hyponatremia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 0, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 1 | 0 | 0 | 0 |
| Hypernatremia , Grade 0, Grade 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Hypernatremia , Grade 1, Grade 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 0, Grade 1 | 1 | 0 | 1 | 1 | 1 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 7 | 5 | 1 | 0 | 0 |
| Hypocalcemia , Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| Hypocalcemia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Hypocalcemia , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Missing, Grade 0 | — | — | — | — | — | — | — | — | — | — | — | — | 1 | — | — | — | — |
| Hypocalcemia , Missing, Grade 1 | — | — | — | — | — | — | — | — | — | — | — | — | 0 | — | — | — | — |
| Hypocalcemia , Missing, Grade 2 | — | — | — | — | — | — | — | — | — | — | — | — | 0 | — | — | — | — |
| Hypocalcemia , Missing, Grade 3 | — | — | — | — | — | — | — | — | — | — | — | — | 0 | — | — | — | — |
| Hypocalcemia , Missing, Grade 4 | — | — | — | — | — | — | — | — | — | — | — | — | 0 | — | — | — | — |
| Hypercalcemia , Grade 0, Grade 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 2 | 1 | 0 | 0 | 0 | 4 | 2 | 1 | 0 | 0 |
| Hypercalcemia , Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hypercalcemia , Grade 0, Grade 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 |
| Hypercalcemia , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 1, Grade 4 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 4 | 0 | 1 |
| Hypercalcemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Missing, Grade 0 | — | — | — | — | — | — | — | — | — | — | — | — | 1 | — | — | — | — |
| Hypercalcemia , Missing, Grade 1 | — | — | — | — | — | — | — | — | — | — | — | — | 0 | — | — | — | — |
| Hypercalcemia , Missing, Grade 2 | — | — | — | — | — | — | — | — | — | — | — | — | 0 | — | — | — | — |
| Hypercalcemia , Missing, Grade 3 | — | — | — | — | — | — | — | — | — | — | — | — | 0 | — | — | — | — |
| Hypercalcemia , Missing, Grade 4 | — | — | — | — | — | — | — | — | — | — | — | — | 0 | — | — | — | — |
| Chronic Kidney Disease , Grade 0, Grade 1 | — | 0 | 0 | 0 | 1 | 1 | — | — | 0 | — | — | 0 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Grade 0, Grade 2 | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | — | — | 0 | 0 | 1 | 0 | — | — |
| Chronic Kidney Disease , Grade 0, Grade 3 | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | — | — | 0 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Grade 0, Grade 4 | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | — | — | 0 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Grade 1, Grade 0 | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | — | — | 0 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Grade 1, Grade 2 | — | 0 | 0 | 1 | 0 | 0 | — | — | 1 | — | — | 0 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Grade 1, Grade 3 | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | — | — | 0 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Grade 1, Grade 4 | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | — | — | 0 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Grade 2, Grade 0 | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | — | — | 0 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Grade 2, Grade 1 | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | — | — | 0 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Grade 2, Grade 3 | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | — | — | 0 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Grade 2, Grade 4 | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | — | — | 0 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Grade 3, Grade 0 | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | — | — | 0 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Grade 3, Grade 1 | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | — | — | 0 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Grade 3, Grade 2 | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | — | — | 0 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Grade 3, Grade 4 | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | — | — | 0 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Grade 4, Grade 0 | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | — | — | 0 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Grade 4, Grade 1 | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | — | — | 0 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Grade 4, Grade 2 | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | — | — | 0 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Grade 4, Grade 3 | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | — | — | 0 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Missing, Grade 0 | — | — | — | 0 | 0 | 0 | — | — | 0 | — | — | 1 | 1 | 0 | 0 | — | — |
| Chronic Kidney Disease , Missing, Grade 1 | — | — | — | 1 | 0 | 1 | — | — | 1 | — | — | 0 | 3 | 1 | 2 | — | — |
| Chronic Kidney Disease , Missing, Grade 2 | — | — | — | 0 | 1 | 0 | — | — | 0 | — | — | 1 | 5 | 0 | 0 | — | — |
| Chronic Kidney Disease , Missing, Grade 3 | — | — | — | 0 | 0 | 0 | — | — | 0 | — | — | 1 | 0 | 0 | 0 | — | — |
| Chronic Kidney Disease , Missing, Grade 4 | — | — | — | 0 | 0 | 1 | — | — | 0 | — | — | 0 | 0 | 1 | 0 | — | — |
Normal ranges were 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
| Participants | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lactate Dehydrogenase (IU/L), To Low | — | — | — | — | — | — | — | — | 0 | 0 | 0 | — | 0 | 0 | 0 | — | 0 |
| Lactate Dehydrogenase (IU/L), To Normal or No Change | — | — | — | — | — | — | — | — | 2 | 2 | 1 | — | 1 | 1 | 3 | — | 1 |
| Lactate Dehydrogenase (IU/L), To High | — | — | — | — | — | — | — | — | 0 | 0 | 0 | — | 0 | 0 | 2 | — | 2 |
| Protein (g/L), To Low | 2 | 2 | 2 | 3 | 1 | 0 | 0 | 0 | 3 | 2 | 0 | 0 | 16 | 6 | 12 | 0 | 2 |
| Protein (g/L), To Normal or No Change | 3 | 3 | 3 | 3 | 8 | 10 | 0 | 4 | 12 | 2 | 3 | 3 | 18 | 6 | 9 | 1 | 1 |
| Protein (g/L), To High | 0 | 0 | 0 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 2 | 3 | 1 | 0 | 0 | 2 |
| Triiodothyronine, Free (pmol/L), To Low | 0 | 0 | 0 | 1 | 4 | 1 | 0 | 0 | 2 | 0 | 0 | 1 | 5 | 4 | 2 | 0 | 0 |
| Triiodothyronine, Free (pmol/L), To Normal or No Change | 2 | 5 | 3 | 6 | 4 | 6 | 1 | 2 | 10 | 2 | 3 | 3 | 26 | 7 | 18 | 1 | 3 |
| Triiodothyronine, Free (pmol/L), To High | 1 | 0 | 1 | 2 | 2 | 3 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 1 |
| Thyroxine, Free (pmol/L), To Low | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 |
| Thyroxine, Free (pmol/L), To Normal or No Change | 3 | 5 | 3 | 6 | 8 | 6 | 1 | 2 | 13 | 2 | 2 | 3 | 31 | 12 | 14 | 1 | 4 |
| Thyroxine, Free (pmol/L), To High | 1 | 0 | 1 | 1 | 0 | 4 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 2 | 0 | 0 |
| Troponin I (ug/L), To Low | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 |
| Troponin I (ug/L), To Normal or No Change | 1 | 1 | 2 | 3 | 4 | 3 | — | 1 | 3 | 2 | 1 | 4 | 11 | 9 | 9 | 1 | 2 |
| Troponin I (ug/L), To High | 1 | 0 | 0 | 1 | 1 | 1 | — | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 6 | 0 | 1 |
| Troponin T (ug/L), To Low | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 0 | — | 0 | — | 0 | 0 | 0 | — | 0 |
| Troponin T (ug/L), To Normal or No Change | 2 | 1 | 1 | 2 | 2 | 3 | — | — | 8 | — | 1 | — | 12 | 2 | 2 | — | 3 |
| Troponin T (ug/L), To High | 0 | 0 | 0 | 1 | 0 | 0 | — | — | 2 | — | 0 | — | 1 | 1 | 0 | — | 0 |
| Thyrotropin (mU/L), To Low | 1 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 |
| Thyrotropin (mU/L), To Normal or No Change | 2 | 5 | 2 | 5 | 6 | 9 | 1 | 1 | 8 | 1 | 2 | 2 | 23 | 11 | 17 | 1 | 3 |
| Thyrotropin (mU/L), To High | 1 | 0 | 1 | 3 | 3 | 0 | 0 | 1 | 4 | 1 | 1 | 2 | 6 | 1 | 3 | 0 | 1 |
| Urea (mmol/L), To Low | 1 | 0 | 0 | 0 | 2 | 2 | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 2 | 0 | 0 | 0 |
| Urea (mmol/L), To Normal or No Change | 3 | 3 | 2 | 4 | 4 | 6 | 1 | 2 | 9 | 2 | 1 | 1 | 17 | 3 | 12 | 1 | 2 |
| Urea (mmol/L), To High | 1 | 1 | 3 | 3 | 4 | 3 | 0 | 1 | 3 | 2 | 1 | 3 | 6 | 8 | 5 | 0 | 2 |
Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.
| Participants | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anemia , Grade 0, Grade 1 | 0 | 1 | 0 | 2 | 4 | 2 | 0 | 1 | 3 | 0 | 2 | 2 | 5 | 2 | 2 | 0 | 1 |
| Anemia , Grade 0, Grade 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 4 | 4 | 4 | 0 | 0 |
| Anemia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 |
| Anemia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 1, Grade 2 | 0 | 3 | 2 | 1 | 2 | 2 | 0 | 0 | 2 | 1 | 1 | 1 | 9 | 2 | 7 | 0 | 1 |
| Anemia , Grade 1, Grade 3 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 5 | 0 | 3 | 0 | 0 |
| Anemia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 2, Grade 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 4 | 1 | 0 | 0 | 0 |
| Anemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 0, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 0, Grade 1 | 0 | 2 | 0 | 1 | 2 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 8 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 0, Grade 2 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 7 | 3 | 3 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 3 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 1, Grade 2 | 1 | 1 | 1 | 0 | 2 | 1 | 0 | 0 | 4 | 0 | 1 | 1 | 3 | 2 | 3 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 2 | 4 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 2, Grade 3 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 4 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 0, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 0, Grade 2 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 0, Grade 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Lymphocyte Count Increased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 0, Grade 1 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 0, Grade 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 8 | 2 | 3 | 0 | 0 |
| Neutrophil Count Decreased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 8 | 5 | 10 | 0 | 0 |
| Neutrophil Count Decreased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 2 | 4 | 0 | 0 |
| Neutrophil Count Decreased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 1, Grade 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 0, Grade 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 13 | 6 | 4 | 1 | 0 |
| Platelet Count Decreased, Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 0 | 0 |
| Platelet Count Decreased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 1 | 1 | 0 | 0 |
| Platelet Count Decreased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 0 | 2 | 0 | 0 |
| Platelet Count Decreased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 1, Grade 3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Platelet Count Decreased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Platelet Count Decreased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 0, Grade 1 | 1 | 0 | 2 | 1 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 4 | 0 | 5 | 0 | 0 |
| White Blood Cell Decreased, Grade 0, Grade 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 11 | 6 | 5 | 0 | 0 |
| White Blood Cell Decreased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 13 | 3 | 7 | 0 | 0 |
| White Blood Cell Decreased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| White Blood Cell Decreased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| White Blood Cell Decreased, Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 0 | 0 |
| White Blood Cell Decreased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 0, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells /L (eosinophils), 41 to 50 percentage of RBC in blood (hematocrit), 2 to 8 percentage of WBC (monocytes), 40 to 60 cells/mcL (neutrophils) and Women: 4.2 to 5.4 million RBC/mcL of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
| Participants | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Basophils, To Low | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 3 | 0 | 0 |
| Basophils, To Normal or No Change | 5 | 3 | 5 | 6 | 11 | 11 | 1 | 4 | 11 | 4 | 3 | 5 | 23 | 9 | 17 | 1 | 2 |
| Basophils, To High | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 3 | 1 | 0 | 2 |
| Eosinophils, To Low | 1 | 2 | 1 | 0 | 3 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 6 | 2 | 6 | 0 | 0 |
| Eosinophils, To Normal or No Change | 4 | 2 | 3 | 5 | 8 | 8 | 1 | 3 | 9 | 4 | 3 | 3 | 23 | 7 | 12 | 1 | 2 |
| Eosinophils, To High | 0 | 0 | 1 | 3 | 1 | 3 | 0 | 1 | 4 | 0 | 0 | 1 | 3 | 6 | 6 | 0 | 2 |
| Hematocrit, To Low | 1 | 1 | 0 | 3 | 4 | 2 | 0 | 0 | 3 | 0 | 2 | 3 | 15 | 7 | 9 | 0 | 0 |
| Hematocrit, To Normal or No Change | 4 | 4 | 5 | 5 | 6 | 9 | 1 | 4 | 11 | 4 | 1 | 1 | 21 | 6 | 12 | 1 | 4 |
| Hematocrit, To High | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| Monocytes, To Low | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 7 | 10 | 0 | 0 |
| Monocytes, To Normal or No Change | 3 | 3 | 4 | 4 | 9 | 9 | 1 | 3 | 12 | 3 | 3 | 2 | 16 | 4 | 6 | 1 | 4 |
| Monocytes, To High | 2 | 2 | 1 | 4 | 2 | 2 | 0 | 1 | 3 | 1 | 0 | 3 | 12 | 6 | 13 | 0 | 0 |
| Neutrophils, To Low | — | — | 0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Neutrophils, To Normal or No Change | — | — | 0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Neutrophils, To High | — | — | 1 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Erythrocytes, To Low | 1 | 1 | 0 | 3 | 6 | 3 | 0 | 0 | 2 | 2 | 2 | 3 | 17 | 9 | 13 | 0 | 2 |
| Erythrocytes, To Normal or No Change | 4 | 4 | 5 | 5 | 4 | 8 | 1 | 4 | 13 | 2 | 1 | 2 | 19 | 4 | 8 | 1 | 2 |
| Erythrocytes, To High | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.
| Participants | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glucose, No Change/Decreased | 5 | 4 | 4 | 8 | 10 | 10 | 1 | 3 | 14 | 4 | 3 | 5 | 33 | 8 | 16 | 1 | 4 |
| Glucose, Any increase | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 5 | 6 | 0 | 0 |
| Ketones, No Change/Decreased | 1 | 5 | 3 | 6 | 9 | 9 | 1 | 4 | 14 | 3 | 2 | 2 | 28 | 7 | 15 | 0 | 3 |
| Ketones, Any increase | 4 | 0 | 2 | 2 | 2 | 2 | 0 | 0 | 1 | 1 | 1 | 4 | 6 | 6 | 7 | 1 | 1 |
| Occult Blood, No Change/Decreased | 3 | 4 | 1 | 4 | 7 | 5 | 1 | 4 | 13 | 3 | 2 | 3 | 23 | 7 | 12 | 1 | 4 |
| Occult Blood, Any increase | 2 | 1 | 4 | 4 | 4 | 6 | 0 | 0 | 2 | 1 | 1 | 3 | 9 | 6 | 10 | 0 | 0 |
Number of participants with dose modifications (including dose delays, dose escalations, and infusion interruptions) were reported for Feladilimab
| Participants | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose delays | 1 | 0 | 1 | 0 | 2 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 4 | 7 | 11 | 0 | 0 |
| Dose escalations | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Infusion interruptions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or Is a congenital anomaly/birth defect, Other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the MedDRA dictionary.
| Participants | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg |
|---|---|---|---|
| Any AEs | 34 | 111 | 55 |
| Any SAEs | 9 | 44 | 19 |
Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.
| Participants | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg |
|---|---|---|---|
| Hypoglycemia , Grade 0, Grade 1 | 4 | 7 | 6 |
| Hypoglycemia , Grade 0, Grade 2 | 0 | 2 | 1 |
| Hypoglycemia , Grade 0, Grade 3 | 0 | 0 | 0 |
| Hypoglycemia , Grade 0, Grade 4 | 0 | 0 | 0 |
| Hypoglycemia , Grade 1, Grade 0 | 1 | 2 | 0 |
| Hypoglycemia , Grade 1, Grade 2 | 0 | 0 | 0 |
| Hypoglycemia , Grade 1, Grade 3 | 0 | 0 | 0 |
| Hypoglycemia , Grade 1, Grade 4 | 0 | 0 | 0 |
| Hypoglycemia , Grade 2, Grade 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 2, Grade 1 | 0 | 0 | 0 |
| Hypoglycemia , Grade 2, Grade 3 | 0 | 0 | 0 |
| Hypoglycemia , Grade 2, Grade 4 | 0 | 0 | 0 |
| Hypoglycemia , Grade 3, Grade 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 3, Grade 1 | 0 | 0 | 0 |
| Hypoglycemia , Grade 3, Grade 2 | 0 | 0 | 0 |
| Hypoglycemia , Grade 3, Grade 4 | 0 | 0 | 0 |
| Hypoglycemia , Grade 4, Grade 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 4, Grade 1 | 0 | 0 | 0 |
| Hypoglycemia , Grade 4, Grade 2 | 0 | 0 | 0 |
| Hypoglycemia , Grade 4, Grade 3 | 0 | 0 | 0 |
| Hypoglycemia , Missing, Grade 0 | — | 2 | 2 |
| Hypoglycemia , Missing, Grade 1 | — | 0 | 1 |
| Hypoglycemia , Missing, Grade 2 | — | 0 | 0 |
| Hypoglycemia , Missing, Grade 3 | — | 0 | 0 |
| Hypoglycemia , Missing, Grade 4 | — | 0 | 0 |
| Hyperglycemia , Grade 0, Grade 1 | 11 | 38 | 19 |
| Hyperglycemia , Grade 0, Grade 2 | 1 | 8 | 3 |
| Hyperglycemia , Grade 0, Grade 3 | 0 | 0 | 0 |
| Hyperglycemia , Grade 0, Grade 4 | 0 | 0 | 0 |
| Hyperglycemia , Grade 1, Grade 0 | 2 | 0 | 1 |
| Hyperglycemia , Grade 1, Grade 2 | 0 | 1 | 4 |
| Hyperglycemia , Grade 1, Grade 3 | 0 | 2 | 0 |
| Hyperglycemia , Grade 1, Grade 4 | 0 | 1 | 0 |
| Hyperglycemia , Grade 2, Grade 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 2, Grade 1 | 0 | 1 | 0 |
| Hyperglycemia , Grade 2, Grade 3 | 0 | 0 | 0 |
| Hyperglycemia , Grade 2, Grade 4 | 0 | 0 | 0 |
| Hyperglycemia , Grade 3, Grade 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 3, Grade 1 | 0 | 0 | 0 |
| Hyperglycemia , Grade 3, Grade 2 | 0 | 0 | 1 |
| Hyperglycemia , Grade 3, Grade 4 | 0 | 0 | 0 |
| Hyperglycemia , Grade 4, Grade 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 4, Grade 1 | 0 | 0 | 0 |
| Hyperglycemia , Grade 4, Grade 2 | 0 | 0 | 0 |
| Hyperglycemia , Grade 4, Grade 3 | 0 | 0 | 0 |
| Hyperglycemia , Missing, Grade 0 | — | 1 | 3 |
| Hyperglycemia , Missing, Grade 1 | — | 1 | 0 |
| Hyperglycemia , Missing, Grade 2 | — | 0 | 0 |
| Hyperglycemia , Missing, Grade 3 | — | 0 | 0 |
| Hyperglycemia , Missing, Grade 4 | — | 0 | 0 |
| Hypoalbuminemia , Grade 0, Grade 1 | 4 | 12 | 10 |
| Hypoalbuminemia , Grade 0, Grade 2 | 1 | 12 | 2 |
| Hypoalbuminemia , Grade 0, Grade 3 | 0 | 0 | 1 |
| Hypoalbuminemia , Grade 0, Grade 4 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 1, Grade 0 | 1 | 1 | 1 |
| Hypoalbuminemia , Grade 1, Grade 2 | 2 | 5 | 2 |
| Hypoalbuminemia , Grade 1, Grade 3 | 0 | 1 | 0 |
| Hypoalbuminemia , Grade 1, Grade 4 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 2, Grade 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 2, Grade 1 | 0 | 0 | 1 |
| Hypoalbuminemia , Grade 2, Grade 3 | 0 | 2 | 1 |
| Hypoalbuminemia , Grade 2, Grade 4 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 3, Grade 0 | 0 | 0 | 1 |
| Hypoalbuminemia , Grade 3, Grade 1 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 3, Grade 2 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 3, Grade 4 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 4, Grade 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 4, Grade 1 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 4, Grade 2 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 4, Grade 3 | 0 | 0 | 0 |
| Hypoalbuminemia , Missing, Grade 0 | — | 1 | — |
| Hypoalbuminemia , Missing, Grade 1 | — | 0 | — |
| Hypoalbuminemia , Missing, Grade 2 | — | 0 | — |
| Hypoalbuminemia , Missing, Grade 3 | — | 0 | — |
| Hypoalbuminemia , Missing, Grade 4 | — | 0 | — |
| AP Increased, Grade 0, Grade 1 | 7 | 20 | 8 |
| AP Increased, Grade 0, Grade 2 | 2 | 3 | 0 |
| AP Increased, Grade 0, Grade 3 | 0 | 0 | 0 |
| AP Increased, Grade 0, Grade 4 | 0 | 0 | 0 |
| AP Increased, Grade 1, Grade 0 | 0 | 1 | 2 |
| AP Increased, Grade 1, Grade 2 | 3 | 9 | 1 |
| AP Increased, Grade 1, Grade 3 | 0 | 1 | 1 |
| AP Increased, Grade 1, Grade 4 | 0 | 0 | 0 |
| AP Increased, Grade 2, Grade 0 | 0 | 0 | 0 |
| AP Increased, Grade 2, Grade 1 | 0 | 0 | 0 |
| AP Increased, Grade 2, Grade 3 | 1 | 0 | 0 |
| AP Increased, Grade 2, Grade 4 | 0 | 0 | 0 |
| AP Increased, Grade 3, Grade 0 | 0 | 0 | 0 |
| AP Increased, Grade 3, Grade 1 | 0 | 0 | 0 |
| AP Increased, Grade 3, Grade 2 | 0 | 0 | 0 |
| AP Increased, Grade 3, Grade 4 | 0 | 0 | 0 |
| AP Increased, Grade 4, Grade 0 | 0 | 0 | 0 |
| AP Increased, Grade 4, Grade 1 | 0 | 0 | 0 |
| AP Increased, Grade 4, Grade 2 | 0 | 0 | 0 |
| AP Increased, Grade 4, Grade 3 | 0 | 0 | 0 |
| AP Increased, Missing, Grade 0 | 1 | — | — |
| AP Increased, Missing, Grade 1 | 0 | — | — |
| AP Increased, Missing, Grade 2 | 0 | — | — |
| AP Increased, Missing, Grade 3 | 0 | — | — |
| AP Increased, Missing, Grade 4 | 0 | — | — |
| ALT Increased, Grade 0, Grade 1 | 4 | 18 | 8 |
| ALT Increased, Grade 0, Grade 2 | 0 | 2 | 1 |
| ALT Increased, Grade 0, Grade 3 | 0 | 1 | 1 |
| ALT Increased, Grade 0, Grade 4 | 0 | 0 | 0 |
| ALT Increased, Grade 1, Grade 0 | 0 | 2 | 0 |
| ALT Increased, Grade 1, Grade 2 | 2 | 0 | 1 |
| ALT Increased, Grade 1, Grade 3 | 0 | 2 | 0 |
| ALT Increased, Grade 1, Grade 4 | 0 | 0 | 0 |
| ALT Increased, Grade 2, Grade 0 | 0 | 0 | 0 |
| ALT Increased, Grade 2, Grade 1 | 0 | 0 | 0 |
| ALT Increased, Grade 2, Grade 3 | 0 | 0 | 0 |
| ALT Increased, Grade 2, Grade 4 | 0 | 0 | 0 |
| ALT Increased, Grade 3, Grade 0 | 0 | 0 | 0 |
| ALT Increased, Grade 3, Grade 1 | 0 | 0 | 0 |
| ALT Increased, Grade 3, Grade 2 | 0 | 0 | 0 |
| ALT Increased, Grade 3, Grade 4 | 0 | 0 | 0 |
| ALT Increased, Grade 4, Grade 0 | 0 | 0 | 0 |
| ALT Increased, Grade 4, Grade 1 | 0 | 0 | 0 |
| ALT Increased, Grade 4, Grade 2 | 0 | 0 | 0 |
| ALT Increased, Grade 4, Grade 3 | 0 | 0 | 0 |
| ALT Increased, Missing, Grade 0 | — | — | 1 |
| ALT Increased, Missing, Grade 1 | — | — | 0 |
| ALT Increased, Missing, Grade 2 | — | — | 0 |
| ALT Increased, Missing, Grade 3 | — | — | 0 |
| ALT Increased, Missing, Grade 4 | — | — | 0 |
| AST Increased, Grade 0, Grade 1 | 9 | 25 | 15 |
| AST Increased, Grade 0, Grade 2 | 0 | 0 | 1 |
| AST Increased, Grade 0, Grade 3 | 0 | 3 | 2 |
| AST Increased, Grade 0, Grade 4 | 0 | 0 | 0 |
| AST Increased, Grade 1, Grade 0 | 0 | 1 | 0 |
| AST Increased, Grade 1, Grade 2 | 1 | 1 | 0 |
| AST Increased, Grade 1, Grade 3 | 0 | 1 | 0 |
| AST Increased, Grade 1, Grade 4 | 0 | 0 | 0 |
| AST Increased, Grade 2, Grade 0 | 0 | 0 | 0 |
| AST Increased, Grade 2, Grade 1 | 0 | 1 | 0 |
| AST Increased, Grade 2, Grade 3 | 0 | 0 | 0 |
| AST Increased, Grade 2, Grade 4 | 0 | 0 | 0 |
| AST Increased, Grade 3, Grade 0 | 0 | 0 | 0 |
| AST Increased, Grade 3, Grade 1 | 0 | 0 | 0 |
| AST Increased, Grade 3, Grade 2 | 0 | 0 | 0 |
| AST Increased, Grade 3, Grade 4 | 0 | 0 | 0 |
| AST Increased, Grade 4, Grade 0 | 0 | 0 | 0 |
| AST Increased, Grade 4, Grade 1 | 0 | 0 | 0 |
| AST Increased, Grade 4, Grade 2 | 0 | 0 | 0 |
| AST Increased, Grade 4, Grade 3 | 0 | 0 | 0 |
| AST Increased, Missing, Grade 0 | — | 1 | — |
| AST Increased, Missing, Grade 1 | — | 0 | — |
| AST Increased, Missing, Grade 2 | — | 0 | — |
| AST Increased, Missing, Grade 3 | — | 0 | — |
| AST Increased, Missing, Grade 4 | — | 0 | — |
| Blood Bilirubin Increased, Grade 0, Grade 1 | 2 | 2 | 1 |
| Blood Bilirubin Increased, Grade 0, Grade 2 | 0 | 1 | 0 |
| Blood Bilirubin Increased, Grade 0, Grade 3 | 1 | 1 | 3 |
| Blood Bilirubin Increased, Grade 0, Grade 4 | 0 | 1 | 1 |
| Blood Bilirubin Increased, Grade 1, Grade 0 | 0 | 1 | 0 |
| Blood Bilirubin Increased, Grade 1, Grade 2 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 1, Grade 3 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 1, Grade 4 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 2, Grade 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 2, Grade 1 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 2, Grade 3 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 2, Grade 4 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 3, Grade 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 3, Grade 1 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 3, Grade 2 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 3, Grade 4 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 4, Grade 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 4, Grade 1 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 4, Grade 2 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 4, Grade 3 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Missing, Grade 0 | — | 2 | — |
| Blood Bilirubin Increased, Missing, Grade 1 | — | 0 | — |
| Blood Bilirubin Increased, Missing, Grade 2 | — | 0 | — |
| Blood Bilirubin Increased, Missing, Grade 3 | — | 1 | — |
| Blood Bilirubin Increased, Missing, Grade 4 | — | 0 | — |
| Creatinine Increased, Grade 0, Grade 1 | 2 | 11 | 9 |
| Creatinine Increased, Grade 0, Grade 2 | 0 | 0 | 1 |
| Creatinine Increased, Grade 0, Grade 3 | 0 | 2 | 0 |
| Creatinine Increased, Grade 0, Grade 4 | 0 | 1 | 0 |
| Creatinine Increased, Grade 1, Grade 0 | 0 | 2 | 1 |
| Creatinine Increased, Grade 1, Grade 2 | 1 | 4 | 0 |
| Creatinine Increased, Grade 1, Grade 3 | 0 | 0 | 0 |
| Creatinine Increased, Grade 1, Grade 4 | 0 | 0 | 0 |
| Creatinine Increased, Grade 2, Grade 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 2, Grade 1 | 0 | 0 | 0 |
| Creatinine Increased, Grade 2, Grade 3 | 0 | 0 | 0 |
| Creatinine Increased, Grade 2, Grade 4 | 0 | 0 | 0 |
| Creatinine Increased, Grade 3, Grade 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 3, Grade 1 | 0 | 0 | 0 |
| Creatinine Increased, Grade 3, Grade 2 | 0 | 0 | 0 |
| Creatinine Increased, Grade 3, Grade 4 | 0 | 0 | 0 |
| Creatinine Increased, Grade 4, Grade 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 4, Grade 1 | 0 | 0 | 0 |
| Creatinine Increased, Grade 4, Grade 2 | 0 | 0 | 0 |
| Creatinine Increased, Grade 4, Grade 3 | 0 | 0 | 0 |
| Creatinine Increased, Missing, Grade 0 | 3 | — | 1 |
| Creatinine Increased, Missing, Grade 1 | 0 | — | 0 |
| Creatinine Increased, Missing, Grade 2 | 0 | — | 0 |
| Creatinine Increased, Missing, Grade 3 | 0 | — | 0 |
| Creatinine Increased, Missing, Grade 4 | 0 | — | 0 |
| Hypokalemia , Grade 0, Grade 1 | 2 | 7 | 4 |
| Hypokalemia , Grade 0, Grade 2 | 0 | 0 | 0 |
| Hypokalemia , Grade 0, Grade 3 | 1 | 0 | 1 |
| Hypokalemia , Grade 0, Grade 4 | 0 | 1 | 0 |
| Hypokalemia , Grade 1, Grade 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 1, Grade 2 | 0 | 0 | 0 |
| Hypokalemia , Grade 1, Grade 3 | 0 | 0 | 1 |
| Hypokalemia , Grade 1, Grade 4 | 0 | 0 | 0 |
| Hypokalemia , Grade 2, Grade 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 2, Grade 1 | 0 | 0 | 0 |
| Hypokalemia , Grade 2, Grade 3 | 0 | 0 | 0 |
| Hypokalemia , Grade 2, Grade 4 | 0 | 0 | 0 |
| Hypokalemia , Grade 3, Grade 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 3, Grade 1 | 0 | 0 | 0 |
| Hypokalemia , Grade 3, Grade 2 | 0 | 0 | 0 |
| Hypokalemia , Grade 3, Grade 4 | 0 | 0 | 0 |
| Hypokalemia , Grade 4, Grade 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 4, Grade 1 | 0 | 0 | 0 |
| Hypokalemia , Grade 4, Grade 2 | 0 | 0 | 0 |
| Hypokalemia , Grade 4, Grade 3 | 0 | 0 | 0 |
| Hyperkalemia , Grade 0, Grade 1 | 1 | 19 | 6 |
| Hyperkalemia , Grade 0, Grade 2 | 2 | 5 | 2 |
| Hyperkalemia , Grade 0, Grade 3 | 0 | 1 | 0 |
| Hyperkalemia , Grade 0, Grade 4 | 1 | 0 | 2 |
| Hyperkalemia , Grade 1, Grade 0 | 0 | 0 | 1 |
| Hyperkalemia , Grade 1, Grade 2 | 0 | 0 | 0 |
| Hyperkalemia , Grade 1, Grade 3 | 0 | 0 | 0 |
| Hyperkalemia , Grade 1, Grade 4 | 0 | 0 | 0 |
| Hyperkalemia , Grade 2, Grade 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 2, Grade 1 | 0 | 0 | 0 |
| Hyperkalemia , Grade 2, Grade 3 | 0 | 0 | 0 |
| Hyperkalemia , Grade 2, Grade 4 | 0 | 0 | 0 |
| Hyperkalemia , Grade 3, Grade 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 3, Grade 1 | 0 | 0 | 0 |
| Hyperkalemia , Grade 3, Grade 2 | 0 | 0 | 0 |
| Hyperkalemia , Grade 3, Grade 4 | 0 | 0 | 0 |
| Hyperkalemia , Grade 4, Grade 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 4, Grade 1 | 0 | 0 | 0 |
| Hyperkalemia , Grade 4, Grade 2 | 0 | 0 | 0 |
| Hyperkalemia , Grade 4, Grade 3 | 0 | 0 | 0 |
| Hyponatremia , Grade 0, Grade 1 | 7 | 24 | 12 |
| Hyponatremia , Grade 0, Grade 2 | 0 | 0 | 0 |
| Hyponatremia , Grade 0, Grade 3 | 1 | 4 | 3 |
| Hyponatremia , Grade 0, Grade 4 | 1 | 1 | 2 |
| Hyponatremia , Grade 1, Grade 0 | 1 | 1 | 0 |
| Hyponatremia , Grade 1, Grade 2 | 0 | 0 | 0 |
| Hyponatremia , Grade 1, Grade 3 | 0 | 2 | 0 |
| Hyponatremia , Grade 1, Grade 4 | 0 | 0 | 1 |
| Hyponatremia , Grade 2, Grade 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 2, Grade 1 | 0 | 0 | 0 |
| Hyponatremia , Grade 2, Grade 3 | 0 | 0 | 0 |
| Hyponatremia , Grade 2, Grade 4 | 0 | 0 | 0 |
| Hyponatremia , Grade 3, Grade 0 | 0 | 0 | 1 |
| Hyponatremia , Grade 3, Grade 1 | 0 | 0 | 0 |
| Hyponatremia , Grade 3, Grade 2 | 0 | 0 | 0 |
| Hyponatremia , Grade 3, Grade 4 | 0 | 0 | 0 |
| Hyponatremia , Grade 4, Grade 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 4, Grade 1 | 0 | 0 | 0 |
| Hyponatremia , Grade 4, Grade 2 | 0 | 0 | 0 |
| Hyponatremia , Grade 4, Grade 3 | 0 | 0 | 0 |
| Hypernatremia , Grade 0, Grade 1 | 3 | 5 | 1 |
| Hypernatremia , Grade 0, Grade 2 | 0 | 0 | 0 |
| Hypernatremia , Grade 0, Grade 3 | 0 | 0 | 0 |
| Hypernatremia , Grade 0, Grade 4 | 0 | 0 | 0 |
| Hypernatremia , Grade 1, Grade 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 1, Grade 2 | 0 | 0 | 0 |
| Hypernatremia , Grade 1, Grade 3 | 0 | 0 | 0 |
| Hypernatremia , Grade 1, Grade 4 | 0 | 0 | 0 |
| Hypernatremia , Grade 2, Grade 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 2, Grade 1 | 0 | 0 | 0 |
| Hypernatremia , Grade 2, Grade 3 | 0 | 0 | 0 |
| Hypernatremia , Grade 2, Grade 4 | 0 | 0 | 0 |
| Hypernatremia , Grade 3, Grade 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 3, Grade 1 | 0 | 0 | 0 |
| Hypernatremia , Grade 3, Grade 2 | 0 | 0 | 0 |
| Hypernatremia , Grade 3, Grade 4 | 0 | 0 | 0 |
| Hypernatremia , Grade 4, Grade 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 4, Grade 1 | 0 | 0 | 0 |
| Hypernatremia , Grade 4, Grade 2 | 0 | 0 | 0 |
| Hypernatremia , Grade 4, Grade 3 | 0 | 0 | 0 |
| Hypocalcemia , Grade 0, Grade 1 | 1 | 9 | 3 |
| Hypocalcemia , Grade 0, Grade 2 | 1 | 0 | 0 |
| Hypocalcemia , Grade 0, Grade 3 | 0 | 2 | 1 |
| Hypocalcemia , Grade 0, Grade 4 | 2 | 1 | 0 |
| Hypocalcemia , Grade 1, Grade 0 | 0 | 2 | 2 |
| Hypocalcemia , Grade 1, Grade 2 | 0 | 0 | 0 |
| Hypocalcemia , Grade 1, Grade 3 | 0 | 0 | 0 |
| Hypocalcemia , Grade 1, Grade 4 | 0 | 0 | 0 |
| Hypocalcemia , Grade 2, Grade 0 | 0 | 1 | 0 |
| Hypocalcemia , Grade 2, Grade 1 | 0 | 1 | 0 |
| Hypocalcemia , Grade 2, Grade 3 | 0 | 0 | 0 |
| Hypocalcemia , Grade 2, Grade 4 | 0 | 0 | 0 |
| Hypocalcemia , Grade 3, Grade 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 3, Grade 1 | 0 | 0 | 0 |
| Hypocalcemia , Grade 3, Grade 2 | 0 | 0 | 0 |
| Hypocalcemia , Grade 3, Grade 4 | 0 | 0 | 0 |
| Hypocalcemia , Grade 4, Grade 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 4, Grade 1 | 0 | 0 | 0 |
| Hypocalcemia , Grade 4, Grade 2 | 0 | 0 | 0 |
| Hypocalcemia , Grade 4, Grade 3 | 0 | 0 | 0 |
| Hypocalcemia , Missing, Grade 0 | — | 1 | — |
| Hypocalcemia , Missing, Grade 1 | — | 0 | — |
| Hypocalcemia , Missing, Grade 2 | — | 0 | — |
| Hypocalcemia , Missing, Grade 3 | — | 0 | — |
| Hypocalcemia , Missing, Grade 4 | — | 0 | — |
| Hypercalcemia , Grade 0, Grade 1 | 5 | 5 | 6 |
| Hypercalcemia , Grade 0, Grade 2 | 0 | 0 | 1 |
| Hypercalcemia , Grade 0, Grade 3 | 0 | 1 | 1 |
| Hypercalcemia , Grade 0, Grade 4 | 0 | 1 | 0 |
| Hypercalcemia , Grade 1, Grade 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 1, Grade 2 | 0 | 2 | 0 |
| Hypercalcemia , Grade 1, Grade 3 | 0 | 1 | 1 |
| Hypercalcemia , Grade 1, Grade 4 | 0 | 0 | 0 |
| Hypercalcemia , Grade 2, Grade 0 | 0 | 0 | 1 |
| Hypercalcemia , Grade 2, Grade 1 | 0 | 0 | 0 |
| Hypercalcemia , Grade 2, Grade 3 | 0 | 0 | 1 |
| Hypercalcemia , Grade 2, Grade 4 | 0 | 0 | 0 |
| Hypercalcemia , Grade 3, Grade 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 3, Grade 1 | 0 | 0 | 0 |
| Hypercalcemia , Grade 3, Grade 2 | 0 | 0 | 0 |
| Hypercalcemia , Grade 3, Grade 4 | 1 | 0 | 0 |
| Hypercalcemia , Grade 4, Grade 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 4, Grade 1 | 0 | 0 | 0 |
| Hypercalcemia , Grade 4, Grade 2 | 0 | 0 | 0 |
| Hypercalcemia , Grade 4, Grade 3 | 0 | 0 | 0 |
| Hypercalcemia , Missing, Grade 0 | — | 1 | — |
| Hypercalcemia , Missing, Grade 1 | — | 0 | — |
| Hypercalcemia , Missing, Grade 2 | — | 0 | — |
| Hypercalcemia , Missing, Grade 3 | — | 0 | — |
| Hypercalcemia , Missing, Grade 4 | — | 0 | — |
| Chronic Kidney Disease , Grade 0, Grade 1 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 0, Grade 2 | 1 | 4 | 0 |
| Chronic Kidney Disease , Grade 0, Grade 3 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 0, Grade 4 | 0 | 1 | 3 |
| Chronic Kidney Disease , Grade 1, Grade 0 | 0 | 1 | 0 |
| Chronic Kidney Disease , Grade 1, Grade 2 | 0 | 2 | 0 |
| Chronic Kidney Disease , Grade 1, Grade 3 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 1, Grade 4 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 2, Grade 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 2, Grade 1 | 0 | 1 | 0 |
| Chronic Kidney Disease , Grade 2, Grade 2 | 1 | 7 | 2 |
| Chronic Kidney Disease , Grade 2, Grade 3 | 0 | 1 | 0 |
| Chronic Kidney Disease , Grade 2, Grade 4 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 3, Grade 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 3, Grade 1 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 3, Grade 2 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 3, Grade 4 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 4, Grade 0 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 4, Grade 1 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 4, Grade 2 | 0 | 0 | 0 |
| Chronic Kidney Disease , Grade 4, Grade 3 | 0 | 0 | 0 |
| Chronic Kidney Disease , Missing, Grade 0 | 1 | 2 | 0 |
| Chronic Kidney Disease , Missing, Grade 1 | 1 | 4 | 3 |
| Chronic Kidney Disease , Missing, Grade 2 | 0 | 1 | 1 |
| Chronic Kidney Disease , Missing, Grade 3 | 0 | 0 | 0 |
| Chronic Kidney Disease , Missing, Grade 4 | 0 | 1 | 0 |
Normal ranges were 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%
| Participants | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg |
|---|---|---|---|
| Lactate Dehydrogenase (IU/L), To Low | 0 | — | 0 |
| Lactate Dehydrogenase (IU/L), To Normal or No Change | 1 | — | 3 |
| Lactate Dehydrogenase (IU/L), To High | 0 | — | 1 |
| Protein (g/L), To Low | 1 | 22 | 9 |
| Protein (g/L), To Normal or No Change | 34 | 80 | 45 |
| Protein (g/L), To High | 2 | 11 | 4 |
| Triiodothyronine, Free (pmol/L), To Low | 5 | 15 | 10 |
| Triiodothyronine, Free (pmol/L), To Normal or No Change | 23 | 74 | 37 |
| Triiodothyronine, Free (pmol/L), To High | 2 | 16 | 4 |
| Thyroxine, Free (pmol/L), To Low | 2 | 14 | 5 |
| Thyroxine, Free (pmol/L), To Normal or No Change | 27 | 78 | 44 |
| Thyroxine, Free (pmol/L), To High | 2 | 12 | 2 |
| Troponin I (ug/L), To Low | 0 | 1 | 0 |
| Troponin I (ug/L), To Normal or No Change | 12 | 27 | 15 |
| Troponin I (ug/L), To High | 2 | 6 | 4 |
| Troponin T (ug/L), To Low | 0 | 0 | 0 |
| Troponin T (ug/L), To Normal or No Change | 18 | 35 | 30 |
| Troponin T (ug/L), To High | 1 | 8 | 2 |
| Thyrotropin (mU/L), To Low | 3 | 4 | 1 |
| Thyrotropin (mU/L), To Normal or No Change | 23 | 82 | 41 |
| Thyrotropin (mU/L), To High | 5 | 19 | 9 |
| Urea (mmol/L), To Low | 1 | 10 | 2 |
| Urea (mmol/L), To Normal or No Change | 26 | 53 | 28 |
| Urea (mmol/L), To High | 6 | 30 | 9 |
Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.
| Participants | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg |
|---|---|---|---|
| Anemia , Grade 0, Grade 1 | 4 | 22 | 7 |
| Anemia , Grade 0, Grade 2 | 2 | 7 | 5 |
| Anemia , Grade 0, Grade 3 | 0 | 4 | 1 |
| Anemia , Grade 0, Grade 4 | 0 | 0 | 0 |
| Anemia , Grade 1, Grade 0 | 0 | 1 | 1 |
| Anemia , Grade 1, Grade 2 | 6 | 20 | 8 |
| Anemia , Grade 1, Grade 3 | 0 | 2 | 1 |
| Anemia , Grade 1, Grade 4 | 0 | 0 | 0 |
| Anemia , Grade 2, Grade 0 | 0 | 0 | 0 |
| Anemia , Grade 2, Grade 1 | 0 | 0 | 0 |
| Anemia , Grade 2, Grade 3 | 1 | 8 | 4 |
| Anemia , Grade 2, Grade 4 | 0 | 0 | 0 |
| Anemia , Grade 3, Grade 0 | 0 | 0 | 0 |
| Anemia , Grade 3, Grade 1 | 0 | 0 | 0 |
| Anemia , Grade 3, Grade 2 | 0 | 0 | 0 |
| Anemia , Grade 3, Grade 4 | 0 | 0 | 0 |
| Anemia , Grade 4, Grade 0 | 0 | 0 | 0 |
| Anemia , Grade 4, Grade 1 | 0 | 0 | 0 |
| Anemia , Grade 4, Grade 2 | 0 | 0 | 0 |
| Anemia , Grade 4, Grade 3 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 0, Grade 1 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 0, Grade 2 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 0, Grade 3 | 0 | 0 | 1 |
| Hemoglobin Increased, Grade 0, Grade 4 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 1, Grade 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 1, Grade 2 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 1, Grade 3 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 1, Grade 4 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 2, Grade 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 2, Grade 1 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 2, Grade 3 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 2, Grade 4 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 3, Grade 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 3, Grade 1 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 3, Grade 2 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 3, Grade 4 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 4, Grade 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 4, Grade 1 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 4, Grade 2 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 4, Grade 3 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 0, Grade 1 | 2 | 22 | 8 |
| Lymphocyte Count Decreased, Grade 0, Grade 2 | 1 | 10 | 6 |
| Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 | 1 | 0 |
| Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 | 1 | 0 |
| Lymphocyte Count Decreased, Grade 1, Grade 0 | 1 | 1 | 0 |
| Lymphocyte Count Decreased, Grade 1, Grade 2 | 5 | 15 | 7 |
| Lymphocyte Count Decreased, Grade 1, Grade 3 | 1 | 4 | 1 |
| Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 2, Grade 1 | 1 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 2, Grade 3 | 3 | 2 | 3 |
| Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Missing, Grade 0 | — | 0 | — |
| Lymphocyte Count Decreased, Missing, Grade 1 | — | 1 | — |
| Lymphocyte Count Decreased, Missing, Grade 2 | — | 3 | — |
| Lymphocyte Count Decreased, Missing, Grade 3 | — | 0 | — |
| Lymphocyte Count Decreased, Missing, Grade 4 | — | 0 | — |
| Lymphocyte Count Increased, Grade 0, Grade 1 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 0, Grade 2 | 0 | 4 | 0 |
| Lymphocyte Count Increased, Grade 0, Grade 3 | 0 | 1 | 1 |
| Lymphocyte Count Increased, Grade 0, Grade 4 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 1, Grade 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 1, Grade 2 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 1, Grade 3 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 1, Grade 4 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 2, Grade 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 2, Grade 1 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 2, Grade 3 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 2, Grade 4 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 3, Grade 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 3, Grade 1 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 3, Grade 2 | 0 | 1 | 0 |
| Lymphocyte Count Increased, Grade 3, Grade 4 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 4, Grade 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 4, Grade 1 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 4, Grade 2 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 4, Grade 3 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Missing, Grade 0 | — | 3 | — |
| Lymphocyte Count Increased, Missing, Grade 1 | — | 0 | — |
| Lymphocyte Count Increased, Missing, Grade 2 | — | 1 | — |
| Lymphocyte Count Increased, Missing, Grade 3 | — | 0 | — |
| Lymphocyte Count Increased, Missing, Grade 4 | — | 0 | — |
| Neutrophil Count Decreased, Grade 0, Grade 1 | 1 | 4 | 2 |
| Neutrophil Count Decreased, Grade 0, Grade 2 | 0 | 0 | 3 |
| Neutrophil Count Decreased, Grade 0, Grade 3 | 0 | 1 | 0 |
| Neutrophil Count Decreased, Grade 0, Grade 4 | 0 | 1 | 0 |
| Neutrophil Count Decreased, Grade 1, Grade 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 1, Grade 2 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 1, Grade 3 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 1, Grade 4 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 2, Grade 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 2, Grade 1 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 2, Grade 3 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 2, Grade 4 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 3, Grade 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 3, Grade 1 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 3, Grade 2 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 3, Grade 4 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 4, Grade 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 4, Grade 1 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 4, Grade 2 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 4, Grade 3 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Missing, Grade 0 | — | 6 | — |
| Neutrophil Count Decreased, Missing, Grade 1 | — | 0 | — |
| Neutrophil Count Decreased, Missing, Grade 2 | — | 0 | — |
| Neutrophil Count Decreased, Missing, Grade 3 | — | 0 | — |
| Neutrophil Count Decreased, Missing, Grade 4 | — | 0 | — |
| Platelet Count Decreased, Grade 0, Grade 1 | 0 | 6 | 2 |
| Platelet Count Decreased, Grade 0, Grade 2 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 0, Grade 3 | 0 | 1 | 0 |
| Platelet Count Decreased, Grade 0, Grade 4 | 0 | 0 | 1 |
| Platelet Count Decreased, Grade 1, Grade 0 | 0 | 1 | 0 |
| Platelet Count Decreased, Grade 1, Grade 2 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 1, Grade 3 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 1, Grade 4 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 2, Grade 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 2, Grade 1 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 2, Grade 3 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 2, Grade 4 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 3, Grade 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 3, Grade 1 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 3, Grade 2 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 3, Grade 4 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 4, Grade 0 | 1 | 0 | 0 |
| Platelet Count Decreased, Grade 4, Grade 1 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 4, Grade 2 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 4, Grade 3 | 0 | 0 | 0 |
| Platelet Count Decreased, Missing, Grade 0 | — | 2 | — |
| Platelet Count Decreased, Missing, Grade 1 | — | 0 | — |
| Platelet Count Decreased, Missing, Grade 2 | — | 0 | — |
| Platelet Count Decreased, Missing, Grade 3 | — | 0 | — |
| Platelet Count Decreased, Missing, Grade 4 | — | 0 | — |
| White Blood Cell Decreased, Grade 0, Grade 1 | 4 | 9 | 3 |
| White Blood Cell Decreased, Grade 0, Grade 2 | 0 | 1 | 2 |
| White Blood Cell Decreased, Grade 0, Grade 3 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 0, Grade 4 | 0 | 2 | 0 |
| White Blood Cell Decreased, Grade 1, Grade 0 | 0 | 1 | 0 |
| White Blood Cell Decreased, Grade 1, Grade 2 | 1 | 2 | 2 |
| White Blood Cell Decreased, Grade 1, Grade 3 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 1, Grade 4 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 2, Grade 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 2, Grade 1 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 2, Grade 3 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 2, Grade 4 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 3, Grade 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 3, Grade 1 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 3, Grade 2 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 3, Grade 4 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 4, Grade 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 4, Grade 1 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 4, Grade 2 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 4, Grade 3 | 0 | 0 | 0 |
| Leukocytosis , Grade 0, Grade 1 | 0 | 0 | 0 |
| Leukocytosis , Grade 0, Grade 2 | 0 | 0 | 0 |
| Leukocytosis , Grade 0, Grade 3 | 0 | 0 | 0 |
| Leukocytosis , Grade 0, Grade 4 | 0 | 0 | 0 |
| Leukocytosis , Grade 1, Grade 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 1, Grade 2 | 0 | 0 | 0 |
| Leukocytosis , Grade 1, Grade 3 | 0 | 0 | 0 |
| Leukocytosis , Grade 1, Grade 4 | 0 | 0 | 0 |
| Leukocytosis , Grade 2, Grade 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 2, Grade 1 | 0 | 0 | 0 |
| Leukocytosis , Grade 2, Grade 3 | 0 | 0 | 0 |
| Leukocytosis , Grade 2, Grade 4 | 0 | 0 | 0 |
| Leukocytosis , Grade 3, Grade 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 3, Grade 1 | 0 | 0 | 0 |
| Leukocytosis , Grade 3, Grade 2 | 0 | 0 | 0 |
| Leukocytosis , Grade 3, Grade 4 | 0 | 0 | 0 |
| Leukocytosis , Grade 4, Grade 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 4, Grade 1 | 0 | 0 | 0 |
| Leukocytosis , Grade 4, Grade 2 | 0 | 0 | 0 |
| Leukocytosis , Grade 4, Grade 3 | 0 | 0 | 0 |
Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells /L (eosinophils), 41 to 50 percentage of RBC in blood (hematocrit), 2 to 8 percentage of WBC (monocytes), and Women: 4.2 to 5.4 million RBC/ mcL of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocyte count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
| Participants | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg |
|---|---|---|---|
| Basophils, To Low | 1 | 3 | 1 |
| Basophils, To Normal or No Change | 35 | 101 | 55 |
| Basophils, To High | 0 | 3 | 2 |
| Eosinophils, To Low | 5 | 11 | 7 |
| Eosinophils, To Normal or No Change | 27 | 85 | 46 |
| Eosinophils, To High | 7 | 18 | 6 |
| Hematocrit, To Low | 8 | 33 | 20 |
| Hematocrit, To Normal or No Change | 28 | 74 | 38 |
| Hematocrit, To High | 2 | 7 | 0 |
| Monocytes, To Low | 0 | 3 | 0 |
| Monocytes, To Normal or No Change | 29 | 92 | 43 |
| Monocytes, To High | 8 | 20 | 15 |
| Erythrocytes, To Low | 8 | 25 | 12 |
| Erythrocytes, To Normal or No Change | 29 | 85 | 45 |
| Erythrocytes, To High | 0 | 4 | 1 |
Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.
| Participants | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg |
|---|---|---|---|
| Glucose, No Change/Decreased | 36 | 104 | 56 |
| Glucose, Any Increase | 2 | 9 | 2 |
| Ketones, No Change/Decreased | 29 | 76 | 46 |
| Ketones, Any Increase | 9 | 37 | 12 |
| Occult Blood, No Change/Decreased | 24 | 70 | 39 |
| Occult Blood, Any Increase | 12 | 40 | 19 |
Number of participants with dose modifications (including dose delays, dose escalation and infusion interruptions) were reported for Feladilimab.
| Participants | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg |
|---|---|---|---|
| Dose delays | 4 | 17 | 5 |
| Dose escalations | 4 | 3 | 0 |
| Infusion interruptions | 0 | 1 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the MedDRA dictionary.
| Participants | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|
| Any AEs | 13 | 250 | 43 | 23 | 4 | 5 | 4 | 1 |
| Any SAEs | 3 | 126 | 17 | 7 | 1 | 2 | 2 | 1 |
Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.
| Participants | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|
| Hypoglycemia , Grade 0, Grade 1 | 0 | 18 | 5 | 1 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 0, Grade 2 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 0, Grade 3 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 0, Grade 4 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 1, Grade 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Hypoglycemia , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 2, Grade 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia , Missing, Grade 0 | — | 1 | — | — | — | — | — | — |
| Hypoglycemia , Missing, Grade 1 | — | 0 | — | — | — | — | — | — |
| Hypoglycemia , Missing, Grade 2 | — | 0 | — | — | — | — | — | — |
| Hypoglycemia , Missing, Grade 3 | — | 0 | — | — | — | — | — | — |
| Hypoglycemia , Missing, Grade 4 | — | 0 | — | — | — | — | — | — |
| Hyperglycemia , Grade 0, Grade 1 | 4 | 91 | 12 | 6 | 1 | 2 | 2 | 0 |
| Hyperglycemia , Grade 0, Grade 2 | 0 | 13 | 0 | 2 | 1 | 1 | 0 | 0 |
| Hyperglycemia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 1, Grade 0 | 0 | 5 | 2 | 0 | 0 | 0 | 1 | 0 |
| Hyperglycemia , Grade 1, Grade 2 | 1 | 22 | 3 | 1 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 1, Grade 3 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 1, Grade 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 2, Grade 1 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 2, Grade 3 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyperglycemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 3, Grade 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 4, Grade 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia , Missing, Grade 0 | — | 1 | — | — | — | — | — | — |
| Hyperglycemia , Missing, Grade 1 | — | 0 | — | — | — | — | — | — |
| Hyperglycemia , Missing, Grade 2 | — | 0 | — | — | — | — | — | — |
| Hyperglycemia , Missing, Grade 3 | — | 0 | — | — | — | — | — | — |
| Hyperglycemia , Missing, Grade 4 | — | 0 | — | — | — | — | — | — |
| Hypoalbuminemia , Grade 0, Grade 1 | 6 | 47 | 7 | 6 | 1 | 2 | 0 | 0 |
| Hypoalbuminemia , Grade 0, Grade 2 | 1 | 12 | 2 | 1 | 0 | 2 | 2 | 0 |
| Hypoalbuminemia , Grade 0, Grade 3 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 1, Grade 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 1, Grade 2 | 1 | 11 | 6 | 2 | 0 | 1 | 0 | 0 |
| Hypoalbuminemia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 2, Grade 3 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia , Missing, Grade 0 | — | 0 | — | — | — | — | — | — |
| Hypoalbuminemia , Missing, Grade 1 | — | 1 | — | — | — | — | — | — |
| Hypoalbuminemia , Missing, Grade 2 | — | 0 | — | — | — | — | — | — |
| Hypoalbuminemia , Missing, Grade 3 | — | 0 | — | — | — | — | — | — |
| Hypoalbuminemia , Missing, Grade 4 | — | 0 | — | — | — | — | — | — |
| AP Increased, Grade 0, Grade 1 | 3 | 50 | 11 | 2 | 0 | 1 | 2 | 0 |
| AP Increased, Grade 0, Grade 2 | 0 | 7 | 1 | 0 | 0 | 1 | 0 | 0 |
| AP Increased, Grade 0, Grade 3 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 1, Grade 2 | 1 | 10 | 3 | 2 | 0 | 0 | 1 | 0 |
| AP Increased, Grade 1, Grade 3 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 2, Grade 3 | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 3, Grade 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AP Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 0, Grade 1 | 2 | 50 | 8 | 4 | 0 | 1 | 2 | 0 |
| ALT Increased, Grade 0, Grade 2 | 1 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 0, Grade 3 | 0 | 2 | 2 | 0 | 0 | 1 | 0 | 0 |
| ALT Increased, Grade 0, Grade 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 1, Grade 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 1, Grade 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 1, Grade 3 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 2, Grade 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 0, Grade 1 | 4 | 65 | 8 | 4 | 0 | 0 | 2 | 0 |
| AST Increased, Grade 0, Grade 2 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
| AST Increased, Grade 0, Grade 3 | 0 | 4 | 2 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 0, Grade 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 1, Grade 0 | 0 | 5 | 3 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 1, Grade 2 | 0 | 7 | 1 | 2 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 1, Grade 3 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 2, Grade 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 2, Grade 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 0, Grade 1 | 0 | 12 | 4 | 1 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 0, Grade 2 | 0 | 7 | 1 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 0, Grade 3 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 0, Grade 4 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 1, Grade 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 1, Grade 3 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 2, Grade 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased, Missing, Grade 0 | — | 1 | — | — | — | — | — | — |
| Blood Bilirubin Increased, Missing, Grade 1 | — | 0 | — | — | — | — | — | — |
| Blood Bilirubin Increased, Missing, Grade 2 | — | 0 | — | — | — | — | — | — |
| Blood Bilirubin Increased, Missing, Grade 3 | — | 0 | — | — | — | — | — | — |
| Blood Bilirubin Increased, Missing, Grade 4 | — | 0 | — | — | — | — | — | — |
| Cpk Increased, Grade 0, Grade 1 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Grade 0, Grade 2 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Grade 0, Grade 3 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Grade 0, Grade 4 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Grade 1, Grade 0 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Grade 1, Grade 2 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Grade 1, Grade 3 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Grade 1, Grade 4 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Grade 2, Grade 0 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Grade 2, Grade 1 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Grade 2, Grade 3 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Grade 2, Grade 4 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Grade 3, Grade 0 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Grade 3, Grade 1 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Grade 3, Grade 2 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Grade 3, Grade 4 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Grade 4, Grade 0 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Grade 4, Grade 1 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Grade 4, Grade 2 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Grade 4, Grade 3 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Missing, Grade 0 | — | — | 1 | — | — | — | — | — |
| Cpk Increased, Missing, Grade 1 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Missing, Grade 2 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Missing, Grade 3 | — | — | 0 | — | — | — | — | — |
| Cpk Increased, Missing, Grade 4 | — | — | 0 | — | — | — | — | — |
| Creatinine Increased, Grade 0, Grade 1 | 2 | 24 | 4 | 6 | 0 | 1 | 0 | 1 |
| Creatinine Increased, Grade 0, Grade 2 | 0 | 9 | 1 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 0, Grade 3 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 0, Grade 4 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 1, Grade 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 1, Grade 2 | 0 | 12 | 0 | 0 | 0 | 0 | 1 | 0 |
| Creatinine Increased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 1, Grade 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 0, Grade 1 | 1 | 30 | 7 | 2 | 1 | 1 | 0 | 0 |
| Hypokalemia , Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 0, Grade 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 1, Grade 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 0, Grade 1 | 1 | 45 | 6 | 4 | 0 | 2 | 0 | 1 |
| Hyperkalemia , Grade 0, Grade 2 | 0 | 8 | 3 | 1 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 0, Grade 3 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 0, Grade 4 | 0 | 4 | 1 | 3 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 1, Grade 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hyperkalemia , Grade 1, Grade 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 2, Grade 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 4, Grade 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 0, Grade 1 | 4 | 52 | 5 | 8 | 0 | 3 | 1 | 0 |
| Hyponatremia , Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 0, Grade 3 | 0 | 10 | 3 | 2 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 0, Grade 4 | 0 | 9 | 1 | 1 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 1, Grade 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 1, Grade 3 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 |
| Hyponatremia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 4, Grade 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 0, Grade 1 | 0 | 9 | 3 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 0, Grade 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 1, Grade 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 0, Grade 1 | 1 | 26 | 2 | 2 | 0 | 1 | 0 | 0 |
| Hypocalcemia , Grade 0, Grade 2 | 0 | 5 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hypocalcemia , Grade 0, Grade 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 0, Grade 4 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 1, Grade 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hypocalcemia , Grade 1, Grade 2 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 1, Grade 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 4, Grade 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia , Missing, Grade 0 | — | 0 | — | — | — | — | — | — |
| Hypocalcemia , Missing, Grade 1 | — | 0 | — | — | — | — | — | — |
| Hypocalcemia , Missing, Grade 2 | — | 0 | — | — | — | — | — | — |
| Hypocalcemia , Missing, Grade 3 | — | 0 | — | — | — | — | — | — |
| Hypocalcemia , Missing, Grade 4 | — | 1 | — | — | — | — | — | — |
| Hypercalcemia , Grade 0, Grade 1 | 2 | 34 | 7 | 9 | 0 | 0 | 2 | 0 |
| Hypercalcemia , Grade 0, Grade 2 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 0, Grade 3 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 0, Grade 4 | 0 | 10 | 1 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 1, Grade 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypercalcemia , Grade 1, Grade 2 | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 1, Grade 3 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 2, Grade 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypercalcemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 3, Grade 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 3, Grade 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 3, Grade 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia , Missing, Grade 0 | — | 0 | — | — | — | — | — | — |
| Hypercalcemia , Missing, Grade 1 | — | 0 | — | — | — | — | — | — |
| Hypercalcemia , Missing, Grade 2 | — | 0 | — | — | — | — | — | — |
| Hypercalcemia , Missing, Grade 3 | — | 0 | — | — | — | — | — | — |
| Hypercalcemia , Missing, Grade 4 | — | 1 | — | — | — | — | — | — |
| Chronic Kidney Disease , Grade 0, Grade 1 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Grade 0, Grade 2 | 0 | 5 | 0 | 1 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Grade 0, Grade 3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Grade 1, Grade 2 | 0 | 11 | 0 | 0 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Grade 2, Grade 3 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Chronic Kidney Disease , Missing, Grade 0 | 0 | 6 | 1 | 1 | — | — | 1 | — |
| Chronic Kidney Disease , Missing, Grade 1 | 2 | 9 | 0 | 1 | — | — | 0 | — |
| Chronic Kidney Disease , Missing, Grade 2 | 1 | 10 | 3 | 4 | — | — | 0 | — |
| Chronic Kidney Disease , Missing, Grade 3 | 0 | 0 | 0 | 0 | — | — | 0 | — |
| Chronic Kidney Disease , Missing, Grade 4 | 0 | 6 | 0 | 1 | — | — | 0 | — |
Normal ranges were 0.1 to 0.3 micromoles (umol)/liter (L) (direct bilirubin); 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); 24-204 ug/L (creatine kinase); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
| Participants | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|
| Direct Bilirubin (umol/L), To Low | — | — | 0 | — | — | — | — | — |
| Direct Bilirubin (umol/L), To Normal or No Change | — | — | 0 | — | — | — | — | — |
| Direct Bilirubin (umol/L), To High | — | — | 1 | — | — | — | — | — |
| Creatine Kinase MB (ug/L), To Low | — | — | 0 | — | — | — | — | — |
| Creatine Kinase MB (ug/L), To Normal or No Change | — | — | 1 | — | — | — | — | — |
| Creatine Kinase MB (ug/L), To High | — | — | 0 | — | — | — | — | — |
| Lactate Dehydrogenase (IU/L), To Low | — | 0 | 0 | 1 | — | — | — | — |
| Lactate Dehydrogenase (IU/L), To Normal or No Change | — | 0 | 2 | 0 | — | — | — | — |
| Lactate Dehydrogenase (IU/L), To High | — | 2 | 2 | 0 | — | — | — | — |
| Protein (g/L), To Low | 1 | 37 | 9 | 2 | 3 | 1 | 1 | 0 |
| Protein (g/L), To Normal or No Change | 11 | 183 | 27 | 18 | 1 | 4 | 2 | 1 |
| Protein (g/L), To High | 2 | 38 | 7 | 4 | 0 | 1 | 2 | 0 |
| Triiodothyronine, Free (pmol/L), To Low | 3 | 41 | 7 | 5 | 0 | 0 | 2 | — |
| Triiodothyronine, Free (pmol/L), To Normal or No Change | 10 | 160 | 29 | 12 | 3 | 5 | 2 | — |
| Triiodothyronine, Free (pmol/L), To High | 0 | 31 | 2 | 3 | 1 | 0 | 0 | — |
| Thyroxine, Free (pmol/L), To Low | 2 | 30 | 6 | 3 | 1 | 0 | 0 | — |
| Thyroxine, Free (pmol/L), To Normal or No Change | 10 | 180 | 30 | 16 | 2 | 3 | 4 | — |
| Thyroxine, Free (pmol/L), To High | 1 | 25 | 2 | 1 | 1 | 0 | 0 | — |
| Troponin I (ug/L), To Low | 0 | 1 | 0 | 2 | 0 | 0 | 0 | — |
| Troponin I (ug/L), To Normal or No Change | 7 | 109 | 18 | 12 | 3 | 2 | 3 | — |
| Troponin I (ug/L), To High | 1 | 15 | 3 | 2 | 0 | 0 | 0 | — |
| Troponin T (ug/L), To Low | — | 0 | 0 | 0 | 0 | 0 | — | — |
| Troponin T (ug/L), To Normal or No Change | — | 44 | 6 | 4 | 1 | 1 | — | — |
| Troponin T (ug/L), To High | — | 13 | 1 | 1 | 0 | 0 | — | — |
| Thyrotropin (mU/L), To Low | 0 | 22 | 1 | 2 | 0 | 1 | 1 | — |
| Thyrotropin (mU/L), To Normal or No Change | 12 | 179 | 29 | 12 | 3 | 4 | 3 | — |
| Thyrotropin (mU/L), To High | 1 | 34 | 8 | 6 | 0 | 1 | 0 | — |
| Urea (mmol/L), To Low | 2 | 33 | 3 | 5 | — | 0 | 1 | — |
| Urea (mmol/L), To Normal or No Change | 9 | 137 | 27 | 10 | — | 1 | 3 | — |
| Urea (mmol/L), To High | 1 | 53 | 6 | 4 | — | 2 | 1 | — |
Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.
| Participants | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|
| Anemia , Grade 0, Grade 1 | 4 | 71 | 13 | 5 | 1 | 2 | 0 | 0 |
| Anemia , Grade 0, Grade 2 | 1 | 9 | 4 | 2 | 0 | 0 | 0 | 0 |
| Anemia , Grade 0, Grade 3 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 1, Grade 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 1, Grade 2 | 3 | 44 | 7 | 4 | 0 | 0 | 2 | 0 |
| Anemia , Grade 1, Grade 3 | 0 | 10 | 0 | 1 | 0 | 1 | 0 | 0 |
| Anemia , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 2, Grade 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Anemia , Grade 2, Grade 3 | 0 | 5 | 1 | 1 | 0 | 0 | 0 | 0 |
| Anemia , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 3, Grade 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 0, Grade 1 | 0 | 5 | 2 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 0, Grade 3 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 1, Grade 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 2, Grade 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 3, Grade 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 0, Grade 1 | 3 | 40 | 7 | 1 | 2 | 1 | 1 | 0 |
| Lymphocyte Count Decreased, Grade 0, Grade 2 | 1 | 24 | 3 | 4 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 0, Grade 3 | 1 | 6 | 1 | 1 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 1, Grade 2 | 3 | 42 | 9 | 5 | 1 | 2 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 | 16 | 1 | 2 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 | 7 | 1 | 3 | 0 | 1 | 2 | 0 |
| Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 3, Grade 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased, Missing, Grade 0 | — | 1 | — | — | — | 0 | — | — |
| Lymphocyte Count Decreased, Missing, Grade 1 | — | 0 | — | — | — | 0 | — | — |
| Lymphocyte Count Decreased, Missing, Grade 2 | — | 1 | — | — | — | 1 | — | — |
| Lymphocyte Count Decreased, Missing, Grade 3 | — | 0 | — | — | — | 0 | — | — |
| Lymphocyte Count Decreased, Missing, Grade 4 | — | 0 | — | — | — | 0 | — | — |
| Lymphocyte Count Increased, Grade 0, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 0, Grade 2 | 1 | 9 | 3 | 1 | 0 | 0 | 1 | 0 |
| Lymphocyte Count Increased, Grade 0, Grade 3 | 0 | 4 | 1 | 1 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 2, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased, Missing, Grade 0 | — | 2 | — | — | — | 1 | — | — |
| Lymphocyte Count Increased, Missing, Grade 1 | — | 0 | — | — | — | 0 | — | — |
| Lymphocyte Count Increased, Missing, Grade 2 | — | 0 | — | — | — | 0 | — | — |
| Lymphocyte Count Increased, Missing, Grade 3 | — | 0 | — | — | — | 0 | — | — |
| Lymphocyte Count Increased, Missing, Grade 4 | — | 0 | — | — | — | 0 | — | — |
| Neutrophil Count Decreased, Grade 0, Grade 1 | 1 | 3 | 3 | 0 | 1 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 0, Grade 2 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 0, Grade 4 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 1, Grade 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 1, Grade 2 | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 1, Grade 3 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 2, Grade 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil Count Decreased, Missing, Grade 0 | — | 2 | — | — | — | 1 | — | — |
| Neutrophil Count Decreased, Missing, Grade 1 | — | 0 | — | — | — | 0 | — | — |
| Neutrophil Count Decreased, Missing, Grade 2 | — | 0 | — | — | — | 0 | — | — |
| Neutrophil Count Decreased, Missing, Grade 3 | — | 0 | — | — | — | 0 | — | — |
| Neutrophil Count Decreased, Missing, Grade 4 | — | 0 | — | — | — | 0 | — | — |
| Platelet Count Decreased, Grade 0, Grade 1 | 0 | 21 | 3 | 0 | 0 | 1 | 0 | 0 |
| Platelet Count Decreased, Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 0, Grade 4 | 0 | 8 | 2 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 1, Grade 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 1, Grade 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 1, Grade 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 4, Grade 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count Decreased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 0, Grade 1 | 1 | 19 | 4 | 1 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 0, Grade 2 | 0 | 4 | 0 | 1 | 1 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 0, Grade 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 1, Grade 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 1, Grade 2 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 1, Grade 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 2, Grade 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 2, Grade 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Decreased, Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 0, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 0, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 0, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 0, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 1, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 1, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 1, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 1, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 2, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 2, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 2, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 2, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 3, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 3, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 3, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 3, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 4, Grade 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 4, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 4, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis , Grade 4, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells/L(eosinophils), 41 to 50 percentage of RBC in blood (hematocrit), 1,000 - 4,800 lymphocytes per microliter (µL) of blood (lymphocytes), 80-100 fl (erythrocytes, mean corpuscular volume), 2 to 8 percentage of WBC (monocytes), 40 to 60 cells/mcL (neutrophils) and Women: 4.2 to 5.4 million RBC/ mcL of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
| Participants | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|
| Basophils, To Low | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basophils, To Normal or No Change | 14 | 224 | 39 | 22 | 4 | 6 | 5 | 1 |
| Basophils, To High | 0 | 10 | 1 | 1 | 0 | 0 | 0 | 0 |
| Eosinophils, To Low | 0 | 22 | 2 | 1 | 0 | 0 | 1 | 0 |
| Eosinophils, To Normal or No Change | 14 | 192 | 29 | 20 | 4 | 6 | 4 | 1 |
| Eosinophils, To High | 0 | 39 | 12 | 2 | 0 | 0 | 0 | 0 |
| Hematocrit, To Low | 4 | 73 | 18 | 7 | 4 | 3 | 0 | 0 |
| Hematocrit, To Normal or No Change | 10 | 169 | 22 | 16 | 0 | 3 | 5 | 1 |
| Hematocrit, To High | 0 | 12 | 3 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes, To Low | — | 2 | 1 | — | — | — | — | — |
| Lymphocytes, To Normal or No Change | — | 0 | 0 | — | — | — | — | — |
| Lymphocytes, To High | — | 0 | 0 | — | — | — | — | — |
| Erythrocytes, Mean Corpuscular Volume, To Low | — | 0 | — | — | — | — | — | — |
| Erythrocytes, Mean Corpuscular Volume, To Normal or No Change | — | 0 | — | — | — | — | — | — |
| Erythrocytes, Mean Corpuscular Volume, To High | — | 1 | — | — | — | — | — | — |
| Monocytes, To Low | 0 | 8 | 2 | 0 | 0 | 0 | 0 | 0 |
| Monocytes, To Normal or No Change | 11 | 181 | 27 | 15 | 2 | 5 | 5 | 1 |
| Monocytes, To High | 3 | 63 | 13 | 8 | 2 | 1 | 0 | 0 |
| Neutrophils, To Low | — | 0 | 0 | — | — | — | — | — |
| Neutrophils, To Normal or No Change | — | 0 | 0 | — | — | — | — | — |
| Neutrophils, To High | — | 2 | 1 | — | — | — | — | — |
| Erythrocytes, To Low | 4 | 66 | 13 | 6 | 0 | 3 | 0 | 0 |
| Erythrocytes, To Normal or No Change | 10 | 180 | 29 | 16 | 3 | 3 | 5 | 1 |
| Erythrocytes, To High | 0 | 12 | 0 | 1 | 1 | 0 | 0 | 0 |
Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.
| Participants | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|
| Glucose, No Change/Decreased | 14 | 228 | 42 | 21 | 4 | 5 | 5 | 1 |
| Glucose, Any increase | 0 | 24 | 2 | 2 | 0 | 0 | 0 | 0 |
| Ketones, No Change/Decreased | 13 | 183 | 31 | 16 | 3 | 4 | 4 | 1 |
| Ketones, Any increase | 1 | 70 | 13 | 7 | 1 | 1 | 1 | 0 |
| Occult Blood, No Change/Decreased | 8 | 129 | 28 | 15 | 3 | 2 | 4 | 1 |
| Occult Blood, Any increase | 3 | 107 | 12 | 7 | 1 | 3 | 1 | 0 |
Number of participants with dose modifications (including dose delays, dose escalations, and infusion interruptions) were reported for Feladilimab.
| Participants | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|
| Dose delays | 2 | 31 | 5 | 1 | 0 | 1 | 0 | 0 |
| Dose escalations | 0 | 10 | 1 | 1 | 0 | 0 | 0 | 0 |
| Infusion interruptions | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 0 |
ORR was defined as the percentage of participants with immune-related confirmed complete response (irCR) or ir confirmed partial response (irPR) per Immune-related Response Evaluation Criteria in Solid Tumors Criteria (irRECIST). irCR is defined as disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
| Percentage of Participants | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Part 1A: Overall Response Rate (ORR) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) | 0 (0.0 to 84.2) | 0 (0.0 to 41.0) | 8 (1.0 to 27.0) | 0 (0.0 to 13.7) | 0 (0.0 to 21.8) | 0 (0.0 to 12.8) | 0 (0.0 to 41.0) |
DCR was defined as percentage of participants with best overall response of irCR or irPR at any time + ir stable disease (irSD) meeting the minimum time criteria from the start of treatment until ir disease progression (irPD) or death due to any cause or the start of new anticancer therapy/crossover. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. irPR defined as at least 30% decrease in the sum of diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. IrPD defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.
| Percentage of Participants | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| >=9 Weeks | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) | 0 (0.0 to 84.2) | 43 (9.9 to 81.6) | 29 (12.6 to 51.1) | 28 (12.1 to 49.4) | 33 (11.8 to 61.6) | 22 (8.6 to 42.3) | 29 (3.7 to 71.0) |
| >=18 Weeks | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) | 0 (0.0 to 84.2) | 14 (0.4 to 57.9) | 17 (4.7 to 37.4) | 24 (9.4 to 45.1) | 13 (1.7 to 40.5) | 7 (0.9 to 24.3) | 0 (0.0 to 41.0) |
OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.
| Months | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Part 1A: Overall Survival (OS) | 4.3 (NA to NA) | 12.6 (NA to NA) | 14.0 (2.0 to 25.9) | 4.9 (3.5 to 8.0) | 6.7 (2.7 to 10.6) | 9.1 (4.0 to 12.9) | 9.1 (3.9 to 17.5) | 6.7 (5.4 to 9.2) | 7.3 (3.8 to NA) |
PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1
| Months | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Part 1A: Progression-free Survival (PFS) | 1.2 (NA to NA) | 1.9 (NA to NA) | 2.1 (2.0 to 2.1) | 2.1 (1.3 to 3.9) | 2.0 (1.5 to 2.1) | 1.9 (1.6 to 3.7) | 2.1 (1.2 to 4.2) | 1.9 (1.8 to 2.1) | 1.9 (1.6 to 4.0) |
TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
| Months | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Part 1A: Time to Overall Response (TTR) | — | — | — | — | 2.3 (NA to NA) | — | — | — | — |
DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.
| Months | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Part 1A: Duration of Response (DOR) | — | — | — | — | 10.3 (NA to NA) | — | — | — | — |
ORR was defined as the percentage of participants with irCR or irPR per irRECIST. irCR is defined as disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
| Percentage of Participants | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 2A: Overall Response Rate (ORR) | 20 (0.5 to 71.6) | 0 (0.0 to 52.2) | 20 (0.5 to 71.6) | 25 (3.2 to 65.1) | 27 (6.0 to 61.0) | 18 (2.3 to 51.8) | 0 (0.0 to 97.5) | 0 (0.0 to 60.2) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 33 (0.8 to 90.6) | 50 (11.8 to 88.2) | 14 (4.7 to 29.5) | 46 (19.2 to 74.9) | 41 (20.7 to 63.6) | 0 (0.0 to 97.5) | 50 (6.8 to 93.2) |
DCR was defined as percentage of participants with best overall response of irCR or irPR at any time + irSD meeting the minimum time criteria from the start of treatment until irPD or death due to any cause or the start of new anticancer therapy/crossover. irCR defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. irPR defined as at least 30% decrease in the sum of diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. IrPD defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.
| Percentage of Participants | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >=9 Weeks | 20 (0.5 to 71.6) | 40 (5.3 to 85.3) | 40 (5.3 to 85.3) | 38 (8.5 to 75.5) | 27 (6.0 to 61.0) | 55 (23.4 to 83.3) | 0 (0.0 to 97.5) | 0 (0.0 to 60.2) | 19 (4.0 to 45.6) | 25 (0.6 to 80.6) | 33 (0.8 to 90.6) | 67 (22.3 to 95.7) | 58 (40.8 to 74.5) | 77 (46.2 to 95.0) | 86 (65.1 to 97.1) | 0 (0.0 to 97.5) | 50 (6.8 to 93.2) |
| >=18 Weeks | 20 (0.5 to 71.6) | 0 (0.0 to 52.2) | 20 (0.5 to 71.6) | 25 (3.2 to 65.1) | 27 (6.0 to 61.0) | 36 (10.9 to 69.2) | 0 (0.0 to 97.5) | 0 (0.0 to 60.2) | 13 (1.6 to 38.3) | 0 (0.0 to 60.2) | 33 (0.8 to 90.6) | 67 (22.3 to 95.7) | 44 (27.9 to 61.9) | 62 (31.6 to 86.1) | 73 (49.8 to 89.3) | 0 (0.0 to 97.5) | 50 (6.8 to 93.2) |
OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.
| Months | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 2A: Overall Survival (OS) | NA (1.1 to NA) | 5.3 (1.9 to NA) | 9.3 (2.2 to 23.5) | 18.4 (6.9 to NA) | 12.7 (3.8 to NA) | 14.6 (4.4 to NA) | 4.1 (NA to NA) | 3.0 (0.8 to 13.9) | 8.2 (3.1 to 10.4) | 6.1 (1.2 to NA) | 8.6 (2.2 to NA) | 7.5 (5.7 to 13.8) | 8.2 (4.9 to 12.6) | 18.5 (9.4 to NA) | 16.1 (10.5 to NA) | NA (NA to NA) | NA (13.2 to NA) |
PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease Progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.
| Months | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 2A: Progression-free Survival (PFS) | 2.0 (1.1 to NA) | 1.9 (0.3 to 3.9) | 1.9 (1.8 to 6.0) | 2.1 (1.5 to 7.6) | 2.1 (1.4 to 7.2) | 2.0 (1.5 to 17.3) | 1.9 (NA to NA) | 1.7 (0.8 to 3.0) | 2.0 (1.4 to 2.1) | 1.6 (1.1 to 4.2) | 2.1 (1.7 to NA) | 5.7 (1.2 to 6.1) | 4.5 (2.6 to 6.0) | 6.7 (1.9 to NA) | 7.3 (4.1 to 10.7) | 1.9 (NA to NA) | NA (2.1 to NA) |
TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
| Months | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 2A: Time to Overall Response (TTR) | 2.1 (NA to NA) | — | 2.0 (NA to NA) | 2.8 (1.4 to 4.1) | 3.0 (1.9 to 4.0) | 11.0 (4.0 to 18.0) | — | — | — | — | 2.1 (NA to NA) | 1.6 (1.3 to 1.9) | 2.1 (2.0 to 4.0) | 1.6 (1.4 to 2.8) | 2.1 (1.4 to 4.2) | — | 2.1 (2.0 to 2.1) |
DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression is defined as the date of radiological disease progression based on imaging data per RECIST v1.1.
| Months | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 2A: Duration of Response (DOR) | NA (NA to NA) | — | 4.1 (NA to NA) | 14.3 (6.3 to 22.2) | NA (3.2 to NA) | 13.8 (NA to NA) | — | — | — | — | NA (NA to NA) | 4.5 (4.2 to 4.8) | 22.5 (4.0 to 22.5) | NA (4.9 to NA) | 6.0 (4.6 to NA) | — | NA (NA to NA) |
ORR was defined as the percentage of participants with a confirmed irCR or confirmed irPR per irRECIST. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
| Percentage of Participants | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg |
|---|---|---|---|
| Part 1B: Overall Response Rate (ORR) | 5 (0.6 to 17.3) | 4 (1.4 to 9.9) | 8 (2.8 to 18.7) |
DCR was defined as percentage of participants with best overall response of irCR or irPR at any time + irSD meeting the minimum time criteria from the start of treatment until irPD or death due to any cause or the start of new anticancer therapy/crossover. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. irPR defined as at least 30% decrease in the sum of diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. IrPD defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.
| Percentage of Participants | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg |
|---|---|---|---|
| >=9 Weeks | 38 (23.4 to 55.4) | 39 (30.2 to 48.7) | 39 (26.5 to 52.6) |
| >=18 Weeks | 23 (11.1 to 39.3) | 23 (15.3 to 31.3) | 19 (9.7 to 30.9) |
OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.
| Months | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg |
|---|---|---|---|
| Part 1B: Overall Survival (OS) | 10.5 (6.7 to 17.3) | 9.4 (7.9 to 12.9) | 7.8 (6.5 to 8.7) |
PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.
| Months | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg |
|---|---|---|---|
| Part 1B: Progression-free Survival (PFS) | 2.1 (2.0 to 3.9) | 2.1 (2.0 to 2.6) | 2.1 (2.0 to 2.3) |
TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
| Months | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg |
|---|---|---|---|
| Part 1B: Time to Overall Response (TTR) | 3.0 (2.0 to 4.0) | 3.0 (2.0 to 3.9) | 3.8 (2.0 to 4.3) |
DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression is defined as the date of radiological disease progression based on imaging data per RECIST v1.1.
| Months | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg |
|---|---|---|---|
| Part 1B: Duration of Response (DOR) | 7.3 (4.2 to 10.4) | 11.8 (6.1 to 17.5) | 7.2 (6.1 to 8.2) |
ORR was defined as the percentage of participants with a confirmed irCR or confirmed irPR per irRECIST. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
| Percentage of Participants | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|
| Part 2B: Overall Response Rate (ORR) | 7 (0.2 to 33.9) | 20 (14.9 to 25.0) | 18 (8.2 to 32.7) | 30 (13.2 to 52.9) | 0 (0.0 to 60.2) | 17 (0.4 to 64.1) | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) |
DCR was defined as the percentage of participants with a best overall response of irCR or irPR at any time plus irSD meeting the minimum time criteria from the start of treatment until irPD or death due to any cause or the start of new anticancer therapy/crossover. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. irPD is defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.
| Percentage of Participants | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|
| >=9 Weeks | 29 (8.4 to 58.1) | 58 (52.1 to 64.5) | 43 (28.3 to 59.0) | 57 (34.5 to 76.8) | 50 (6.8 to 93.2) | 33 (4.3 to 77.7) | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) |
| >=18 Weeks | 21 (4.7 to 50.8) | 39 (32.8 to 45.1) | 27 (15.0 to 42.8) | 35 (16.4 to 57.3) | 25 (0.6 to 80.6) | 33 (4.3 to 77.7) | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) |
OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.
| Months | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|
| Part 2B: Overall Survival (OS) | 8.9 (3.4 to 15.6) | 12.5 (10.1 to 15.2) | 12.1 (8.9 to 19.9) | 10.8 (5.3 to 28.1) | NA (2.3 to NA) | NA (2.7 to NA) | 4.7 (0.5 to NA) | 1.1 (NA to NA) |
PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.
| Months | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|
| Part 2B: Progression-free Survival (PFS) | 2.6 (1.1 to 4.2) | 3.9 (2.8 to 4.0) | 2.3 (2.0 to 4.0) | 4.4 (2.1 to 6.4) | 2.1 (1.1 to 8.4) | 3.1 (1.4 to 13.7) | 1.5 (0.5 to 2.3) | 0.8 (NA to NA) |
TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
| Months | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|
| Part 2B: Time to Overall Response (TTR) | 2.1 (NA to NA) | 2.1 (2.0 to 3.9) | 2.0 (1.3 to 2.6) | 2.1 (1.9 to 4.1) | — | 2.2 (NA to NA) | — | — |
DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression is defined as the date of radiological disease progression based on imaging data per RECIST v1.1
| Months | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|
| Part 2B: Duration of Response (DOR) | 6.1 (NA to NA) | 13.8 (8.3 to 19.5) | 18.7 (4.3 to 38.0) | 24.6 (2.6 to 24.6) | — | 11.5 (NA to NA) | — | — |
Blood samples were collected for Pharmacokinetic (PK) analysis. PK analysis was calculated based on standard non-compartmental method.
| Microgram/millilitre (ug/mL) | Part 1A: Fela 0.003 mg/kg | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Cmax, Cycle 1 | 0.0887 ± NA | NA ± NA | 0.2038 ± 12.6253 | 1.7433 ± 90.5940 | 2.3041 ± 14.0076 | 6.4643 ± 23.7989 | 18.3809 ± 24.4093 | 74.7985 ± 16.0934 | 193.7782 ± 17.1955 |
| Ctau, Cycle 1 | NA ± NA | NA ± NA | — | — | 0.2868 ± 62.2180 | 1.0533 ± 9.2565 | 4.3093 ± 21.6033 | 11.3112 ± 85.3459 | 38.0810 ± 22.3643 |
| Ctau, Cycle 6 | NA ± NA | NA ± NA | — | 0.2426 ± NA | 0.3510 ± NA | — | 11.9562 ± NA | — | 35.9660 ± NA |
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
| Hour*microgram/millilitre (h*ug/mL) | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Part 1A: Area Under the Concentration-time Curve From Time 0 to 504 Hours After Dosing [AUC (0-504h)] of Feladilimab | — | — | — | 134.6206 ± NA | 373.6877 ± 23.2053 | 1156.5768 ± 6.8031 | 4839.0026 ± NA | 11368.0960 ± NA | — |
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
| ug/mL | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg |
|---|---|---|---|---|---|---|
| Cycle 1 | 10.8032 ± 55.7461 | 19.2951 ± 41.0160 | 16.7039 ± 47.9340 | 13.9035 ± 31.9060 | 12.9277 ± 42.3634 | 15.1724 ± 40.5000 |
| Cycle 6 | 35.1000 ± NA | 62.3000 ± NA | — | 35.3321 ± 21.9877 | 35.6000 ± NA | 35.6444 ± 63.8554 |
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
| h*ug/mL | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg |
|---|---|---|---|---|---|---|
| Part 2A: AUC (0-504h) of Pembrolizumab | 11363.9193 ± NA | — | — | 11556.7001 ± NA | 19158.7768 ± NA | 17928.7606 ± 32.2374 |
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
| ug/mL | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg |
|---|---|---|---|---|---|
| Cmax, Cycle 1 | — | 5.1078 ± 27.7040 | 6.6367 ± 47.5930 | 5.5967 ± 10.5455 | 22.7767 ± 13.7397 |
| Ctau, Cycle 1 | — | 0.6700 ± NA | 0.6484 ± 52.4342 | 0.5893 ± 72.0699 | 4.5862 ± 50.0449 |
| Ctau, Cycle 6 | — | — | 0.5663 ± 94.4364 | — | — |
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
| h*ug/mL | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg |
|---|---|---|---|---|---|
| Part 2A: AUC (0-504 h) of GSK3174998 | — | 1038.4544 ± NA | 953.0313 ± 9.2381 | 703.8874 ± 2.7723 | 4606.4365 ± 21.6164 |
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
| ug/mL | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg |
|---|---|---|---|
| BIOMARKER, Cmax, Cycle 1 | — | — | 6.9732 ± 25.8747 |
| BIOMARKER, Ctau, Cycle 1 | — | — | 1.1411 ± 45.6223 |
| BIOMARKER, Ctau, Cycle 6 | — | — | 2.0597 ± 61.8911 |
| BLADDER/UROTHELIAL, Cmax, Cycle 1 | 3.2855 ± 98.7868 | 25.8491 ± 15.5203 | — |
| BLADDER/UROTHELIAL, Ctau, Cycle 1 | 0.5029 ± 151.5778 | 5.3950 ± 39.3125 | — |
| BLADDER/UROTHELIAL, Ctau, Cycle 6 | — | 13.6665 ± 21.8363 | — |
| CERVICAL, Cmax, Cycle 1 | — | 27.2607 ± 28.7319 | — |
| CERVICAL, Ctau, Cycle 1 | — | 3.8347 ± 51.9848 | — |
| CERVICAL, Ctau, Cycle 6 | — | 12.7002 ± 14.0710 | — |
| JAPAN PK/PD, Cmax, Cycle 1 | 5.8973 ± 10.9555 | 22.4768 ± 11.3862 | — |
| JAPAN PK/PD, Ctau, Cycle 1 | 1.2533 ± 9.3514 | 5.1381 ± 12.9597 | — |
| JAPAN PK/PD, Ctau, Cycle 6 | — | 10.9800 ± NA | — |
| MELANOMA, Cmax, Cycle 1 | 6.2711 ± 24.5290 | 23.9959 ± 23.9522 | — |
| MELANOMA, Ctau, Cycle 1 | 1.2025 ± 33.0632 | 4.3924 ± 55.2035 | — |
| MELANOMA, Ctau, Cycle 6 | 2.6320 ± 46.3462 | 11.2405 ± 32.8873 | — |
| MSI-H/DMMR, Cmax, Cycle 1 | 5.4181 ± 38.5999 | 25.6766 ± 27.3384 | — |
| MSI-H/DMMR, Ctau, Cycle 1 | 0.9976 ± 41.4153 | 5.1437 ± 46.0134 | — |
| MSI-H/DMMR, Ctau, Cycle 6 | 2.5409 ± 61.5161 | 9.7769 ± 143.2225 | — |
| NSCLC, Cmax, Cycle 1 | 8.4009 ± 38.8531 | 24.2697 ± 29.1958 | — |
| NSCLC, Ctau, Cycle 1 | 1.4713 ± 39.3325 | 5.4292 ± 55.3073 | — |
| NSCLC, Ctau, Cycle 6 | 4.2630 ± NA | 8.6574 ± 62.7001 | — |
| VIRAL-POSITIVE, Cmax, Cycle 1 | — | 24.2995 ± 25.3201 | — |
| VIRAL-POSITIVE, Ctau, Cycle 1 | — | 5.0751 ± 45.1953 | — |
| VIRAL-POSITIVE, Ctau, Cycle 6 | — | 11.0416 ± 36.7974 | — |
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
| h*ug/mL | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg |
|---|---|---|---|
| BIOMARKER | — | — | 1076.8681 ± 27.3988 |
| BLADDER/UROTHELIAL | 632.0762 ± NA | 5026.8004 ± 24.5736 | — |
| CERVICAL | — | 5222.1970 ± 5.6103 | — |
| JAPAN PK/PD | 1237.7314 ± 9.6008 | 4525.7373 ± 5.5353 | — |
| MELANOMA | 1206.7402 ± 18.6679 | 4048.7261 ± 29.9449 | — |
| MSI-H/DMMR | 1048.2771 ± 24.6105 | 5952.2979 ± 59.1357 | — |
| NSCLC | — | 4731.8292 ± 31.1548 | — |
| VIRAL-POSITIVE | — | 4337.5163 ± 26.4590 | — |
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
| ug/mL | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|
| BLADDER/UROTHELIAL, Cmax, Cycle 1 | — | 7.0435 ± 16.0950 | — | — | — | — | — | — |
| BLADDER/UROTHELIAL, Ctau, Cycle 1 | — | 1.1346 ± 49.2057 | — | — | — | — | — | — |
| BLADDER/UROTHELIAL, Ctau, Cycle 6 | — | 2.5980 ± 39.5677 | — | — | — | — | — | — |
| CERVICAL, Cmax, Cycle 1 | — | 7.8457 ± 25.6236 | 31.0460 ± NA | — | — | — | — | — |
| CERVICAL, Ctau, Cycle 1 | — | 1.1026 ± 86.6644 | 8.3270 ± NA | — | — | — | — | — |
| CERVICAL, Ctau, Cycle 6 | — | 3.5457 ± 51.5684 | 19.2960 ± NA | — | — | — | — | — |
| HNSCC Q6W, Cmax, Cycle 1 | — | — | — | — | — | 12.7362 ± 35.6947 | 70.9208 ± 22.9901 | — |
| HNSCC Q6W, Ctau, Cycle 1 | — | — | — | — | — | — | 6.6970 ± NA | — |
| HNSCC RANDOMIZED, Cmax, Cycle 1 | 2.2993 ± 35.4890 | 6.8500 ± NA | 21.7283 ± 27.2945 | 71.1264 ± 25.9928 | — | — | — | — |
| HNSCC RANDOMIZED, Ctau, Cycle 1 | 0.3314 ± 75.4863 | 1.2350 ± NA | 4.3179 ± 32.9785 | 14.0320 ± 34.6240 | — | — | — | — |
| HNSCC RANDOMIZED, Ctau, Cycle 6 | 0.4949 ± 141.2509 | — | 15.0674 ± 100.4531 | 78.2867 ± 251.8571 | — | — | — | — |
| HNSCC_CPS<1, Cmax, Cycle 1 | — | — | — | — | 11.7572 ± 72.5188 | — | — | 39.4240 ± NA |
| HNSCC_CPS<1, Ctau, Cycle 1 | — | — | — | — | 1.4240 ± NA | — | — | — |
| JAPAN PK/PD, Cmax, Cycle 1 | — | 7.8198 ± 7.7572 | 21.5695 ± 8.9060 | 69.9207 ± 31.4654 | — | — | — | — |
| JAPAN PK/PD, Ctau, Cycle 1 | — | 0.8800 ± 77.4102 | 4.3511 ± 28.1270 | 15.7566 ± 16.4440 | — | — | — | — |
| JAPAN PK/PD, Ctau, Cycle 6 | — | — | — | 37.7140 ± NA | — | — | — | — |
| MELANOMA, Cmax, Cycle 1 | — | 8.3936 ± 43.1529 | 25.7542 ± 12.1953 | — | — | — | — | — |
| MELANOMA, Ctau, Cycle 1 | — | 1.4839 ± 42.9808 | 4.2946 ± 47.1494 | — | — | — | — | — |
| MELANOMA, Ctau, Cycle 6 | — | 3.2491 ± 66.9061 | 8.3404 ± 58.4213 | — | — | — | — | — |
| MSI-H/DMMR, Cmax, Cycle 1 | — | 7.4487 ± 20.8910 | — | — | — | — | — | — |
| MSI-H/DMMR, Ctau, Cycle 1 | — | 1.2458 ± 75.5891 | — | — | — | — | — | — |
| MSI-H/DMMR, Ctau, Cycle 6 | — | 3.3140 ± 32.6114 | — | — | — | — | — | — |
| NSCLC, Cmax, Cycle 1 | — | 8.1306 ± 47.5103 | 16.0295 ± 88.7297 | — | — | — | — | — |
| NSCLC, Ctau, Cycle 1 | — | 1.0848 ± 63.6879 | 2.7263 ± 66.3138 | — | — | — | — | — |
| NSCLC, Ctau, Cycle 6 | — | 3.0399 ± 53.4515 | — | — | — | — | — | — |
| VIRAL-POSITIVE, Cmax, Cycle 1 | — | 7.5533 ± 20.0814 | — | — | — | — | — | — |
| VIRAL-POSITIVE, Ctau, Cycle 1 | — | 1.0357 ± 66.5632 | — | — | — | — | — | — |
| VIRAL-POSITIVE, Ctau, Cycle 6 | — | 1.9175 ± 77.2467 | — | — | — | — | — | — |
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
| h*ug/mL | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 80 mg + Pembro 200 mg |
|---|---|---|---|---|---|---|
| BLADDER/UROTHELIAL | — | 1205.2673 ± 24.3543 | — | — | — | — |
| CERVICAL | — | 1254.7759 ± 39.2813 | — | — | — | — |
| HNSCC RANDOMIZED | 294.2888 ± 46.7592 | 1500.4305 ± NA | 4225.4602 ± 33.1105 | 13829.6005 ± 18.4367 | — | — |
| JAPAN PK/PD | — | 1367.0149 ± 359.19195 | 4258.3090 ± 280.08094 | 13890.8203 ± NA | — | — |
| MELANOMA | — | 1082.3162 ± 48.1386 | 4098.4237 ± 45.2413 | — | — | — |
| MSI-H/DMMR | — | 1264.0452 ± 280.10101 | — | — | — | — |
| NSCLC | — | 1318.6658 ± 664.64033 | 3071.5346 ± 1879.01269 | — | — | — |
| VIRAL-POSITIVE | — | 1415.2121 ± 355.25950 | — | — | — | — |
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
| h*ug/mL | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg |
|---|---|---|
| Part 2B: AUC (0-1008 h) of Feladilimab | 3829.5867 ± NA | 22182.5834 ± NA |
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
No measurements were reported for this outcome.
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
No measurements were reported for this outcome.
Serum samples collected and tested for the presence of ADA with a screening assay.
| Participants | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Part 1A: Number of Participants With Positive Results in Anti-drug Antibody (ADA) Test by Feladilimab Dose Level | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
Serum samples collected and tested for the presence of ADA with a screening assay.
| Participants | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg |
|---|---|---|---|---|---|
| Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab in Combination With GSK3174998 Dose Level | 0 | 0 | 1 | 0 | 0 |
Serum samples collected and tested for the presence of ADA with a screening assay.
| Participants | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg |
|---|---|---|---|---|---|---|
| Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level in Combination With Pembrolizumab | 1 | 0 | 0 | 0 | 0 | 0 |
Serum samples collected and tested for the presence of ADA with a screening assay.
| Participants | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg |
|---|---|---|---|---|---|---|
| Part 2A: Number of Participants With Positive Results in ADA in Pembrolizumab | 0 | 0 | 0 | 0 | 0 | 0 |
Serum samples collected and tested for the presence of ADA with a screening assay.
| Participants | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg |
|---|---|---|---|---|---|
| Part 2A: Number of Participants With Positive Results in ADA in GSK3174998 | 0 | 0 | 1 | 0 | 0 |
Serum samples collected and tested for the presence of ADA with a screening assay.
| Participants | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy |
|---|---|---|---|---|
| Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Combination With Chemotherapies Dose Level | 0 | 0 | 0 | 0 |
Serum samples collected and tested for the presence of ADA with a screening assay.
| Participants | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg |
|---|---|---|---|
| Part 1B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level | 0 | 0 | 1 |
Serum samples collected and tested for the presence of ADA with a screening assay.
| Participants | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|
| Part 2B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
Serum samples collected and tested for the presence of ADA with a screening assay.
| Participants | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|
| Part 2B: Number of Participants With Positive Results in ADA in Pembrolizumab | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.
| percent receptor occupancy | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| %CD4+ | — | — | 74.643 ± NA | 25.406 ± 21.423 | 90.229 ± 9.932 | 96.559 ± 2.934 | 94.007 ± 7.904 | 99.553 ± 1.559 | 96.030 ± 6.652 |
| %CD8+ | — | — | 70.043 ± NA | 16.646 ± 283.345 | 76.985 ± 16.349 | 80.933 ± 23.480 | 88.546 ± 10.383 | 95.934 ± 7.156 | 82.965 ± 29.404 |
Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.
| percent receptor occupancy | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8/24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24/80 mg | Part 2A: Fela 24 mg + Chemotherapy (+/-Pembrolizumab) | Part 2A: Fela 80 mg + Chemotherapy (+/- Pembrolizumab) | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| %CD4+ | 87.351 ± 4.630 | — | 97.962 ± 2.282 | 98.244 ± 1.888 | 99.364 ± 1.333 | 99.704 ± 0.995 | 93.157 ± 1.017 | 97.324 ± 3.753 | 99.887 ± 0.176 | 96.417 ± 7.179 | 94.324 ± 36.547 | — | — |
| %CD8+ | 82.973 ± 13.323 | — | 99.782 ± 4.173 | 93.448 ± 10.622 | 97.995 ± 3.700 | 100.887 ± 2.264 | 79.261 ± 4.878 | 93.221 ± 8.141 | 96.540 ± 4.157 | 94.960 ± 7.366 | 101.528 ± 18.835 | — | — |
Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.
| percent receptor occupancy | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg |
|---|---|---|---|
| %CD4+ | 96.520 ± 4.258 | 99.179 ± 3.926 | 98.128 ± 2.192 |
| %CD8+ | 90.111 ± 11.700 | 96.160 ± 9.429 | 81.219 ± 21.037 |
Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.
| percent receptor occupancy | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|
| %CD4+ | 95.795 ± 4.267 | 95.750 ± 8.757 | 99.004 ± 1.658 | 99.988 ± 0.827 | 87.194 ± NA | 101.663 ± 2.364 | 100.790 ± 1.198 | — |
| %CD8+ | 89.773 ± 8.360 | 93.581 ± 9.049 | 96.900 ± 4.013 | 102.610 ± 9.138 | 57.856 ± NA | 106.059 ± 14.555 | 103.802 ± 6.179 | — |
Collected over All-cause mortality, non-serious adverse events (non-SAEs) and serious adverse events (SAEs) were collected up to approximately 367 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| Part 1A: Fela 0.003 mg/kg | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| Part 1A: Fela 0.010 mg/kg | 2/2 (100%) | 1/2 (50%) | 2/2 (100%) |
| Part 1A: Fela 0.030 mg/kg | 7/7 (100%) | 2/7 (28.6%) | 7/7 (100%) |
| Part 1A: Fela 0.100 mg/kg | 18/24 (75%) | 6/24 (25%) | 19/24 (79.2%) |
| Part 1A: Fela 0.300 mg/kg | 17/25 (68%) | 8/25 (32%) | 23/25 (92%) |
| Part 1A: Fela 1.000 mg/kg | 11/15 (73.3%) | 4/15 (26.7%) | 12/15 (80%) |
| Part 1A: Fela 3.000 mg/kg | 21/27 (77.8%) | 12/27 (44.4%) | 17/27 (63%) |
| Part 1A: Fela 10.000 mg/kg | 3/7 (42.9%) | 1/7 (14.3%) | 6/7 (85.7%) |
| Part 1B: Fela 0.300 mg/kg | 25/39 (64.1%) | 9/39 (23.1%) | 32/39 (82.1%) |
| Part 1B: Fela 1.000 mg/kg | 69/115 (60%) | 44/115 (38.3%) | 101/115 (87.8%) |
| Part 1B: Fela 24 mg | 48/59 (81.4%) | 19/59 (32.2%) | 51/59 (86.4%) |
| Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | 2/5 (40%) | 3/5 (60%) | 5/5 (100%) |
| Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | 4/5 (80%) | 2/5 (40%) | 5/5 (100%) |
| Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | 5/5 (100%) | 3/5 (60%) | 5/5 (100%) |
| Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | 6/8 (75%) | 2/8 (25%) | 5/8 (62.5%) |
| Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | 6/11 (54.5%) | 3/11 (27.3%) | 8/11 (72.7%) |
| Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | 7/11 (63.6%) | 4/11 (36.4%) | 10/11 (90.9%) |
| Part 2A: Fela 8 mg + GSK3174998 8 mg | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) |
| Part 2A: Fela 8 mg + GSK3174998 24 mg | 3/4 (75%) | 2/4 (50%) | 4/4 (100%) |
| Part 2A: Fela 24 mg + GSK3174998 24 mg | 13/16 (81.3%) | 5/16 (31.3%) | 14/16 (87.5%) |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | 3/4 (75%) | 2/4 (50%) | 3/4 (75%) |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 2A: Fela 24 mg + Chemotherapy | 4/6 (66.7%) | 4/6 (66.7%) | 6/6 (100%) |
| Part 2A: Fela 80 mg + Chemotherapy | 31/36 (86.1%) | 13/36 (36.1%) | 36/36 (100%) |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | 7/13 (53.8%) | 3/13 (23.1%) | 13/13 (100%) |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | 13/22 (59.1%) | 17/22 (77.3%) | 22/22 (100%) |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | 1/4 (25%) | 1/4 (25%) | 4/4 (100%) |
| Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | 12/14 (85.7%) | 3/14 (21.4%) | 13/14 (92.9%) |
| Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | 202/255 (79.2%) | 126/255 (49.4%) | 236/255 (92.5%) |
| Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | 31/44 (70.5%) | 17/44 (38.6%) | 40/44 (90.9%) |
| Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | 17/23 (73.9%) | 7/23 (30.4%) | 21/23 (91.3%) |
| Part 2B: Fela 24 mg + Pembro 200 mg | 2/4 (50%) | 1/4 (25%) | 4/4 (100%) |
| Part 2B: Fela 48 mg + Pembro 400 mg | 3/6 (50%) | 2/6 (33.3%) | 5/6 (83.3%) |
| Part 2B: Fela 160 mg + Pembro 400 mg | 3/5 (60%) | 2/5 (40%) | 4/5 (80%) |
| Part 2B: Fela 80 mg + Pembro 200 mg | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| Crossover: Fela 0.100 mg/kg + Pembro 200 mg | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| Crossover: Fela 0.300 mg/kg + Pembro 200 mg | 14/19 (73.7%) | 4/19 (21.1%) | 15/19 (78.9%) |
| Crossover: Fela 1.000 mg/kg + Pembro 200 mg | 32/42 (76.2%) | 12/42 (28.6%) | 26/42 (61.9%) |
| Crossover: Fela 3.000 mg/kg + Pembro 200 mg | 2/2 (100%) | 1/2 (50%) | 1/2 (50%) |
| Crossover: Fela 24 mg + Pembro 200 mg | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| Crossover: Pembro 200 mg | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg | Crossover: Fela 0.100 mg/kg + Pembro 200 mg | Crossover: Fela 0.300 mg/kg + Pembro 200 mg | Crossover: Fela 1.000 mg/kg + Pembro 200 mg | Crossover: Fela 3.000 mg/kg + Pembro 200 mg | Crossover: Fela 24 mg + Pembro 200 mg | Crossover: Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AstheniaGeneral disorders | 0/1 | 0/1 | 0/2 | 0/7 | 0/24 | 0/25 | 0/15 | 0/27 | 0/7 | 0/39 | 0/115 | 1/59 | 0/5 | 0/5 | 0/5 | 0/8 | 0/11 | 1/11 | 0/1 | 0/4 | 0/16 | 0/4 | 0/3 | 0/6 | 0/36 | 0/13 | 0/22 | 0/1 | 0/4 | 0/14 | 2/255 | 0/44 | 0/23 | 0/4 | 0/6 | 0/5 | 1/1 | 0/1 | 0/19 | 1/42 | 0/2 | 0/1 | 0/1 |
| Small intestinal obstructionGastrointestinal disorders | 0/1 | 0/1 | 1/2 | 0/7 | 0/24 | 0/25 | 0/15 | 0/27 | 0/7 | 0/39 | 0/115 | 0/59 | 0/5 | 0/5 | 0/5 | 0/8 | 0/11 | 0/11 | 0/1 | 0/4 | 0/16 | 0/4 | 0/3 | 0/6 | 0/36 | 0/13 | 0/22 | 0/1 | 0/4 | 0/14 | 2/255 | 0/44 | 0/23 | 0/4 | 0/6 | 0/5 | 0/1 | 0/1 | 0/19 | 0/42 | 0/2 | 0/1 | 0/1 |
| OverdoseInjury, poisoning and procedural complications | 0/1 | 0/1 | 0/2 | 0/7 | 0/24 | 0/25 | 0/15 | 0/27 | 0/7 | 0/39 | 0/115 | 0/59 | 0/5 | 0/5 | 0/5 | 0/8 | 0/11 | 0/11 | 0/1 | 0/4 | 0/16 | 0/4 | 0/3 | 0/6 | 0/36 | 0/13 | 0/22 | 0/1 | 0/4 | 0/14 | 0/255 | 0/44 | 0/23 | 0/4 | 0/6 | 0/5 | 0/1 | 0/1 | 0/19 | 0/42 | 1/2 | 0/1 | 0/1 |
| General physical health deteriorationGeneral disorders | 0/1 | 0/1 | 0/2 | 0/7 | 0/24 | 0/25 | 0/15 | 0/27 | 0/7 | 0/39 | 4/115 | 0/59 | 0/5 | 0/5 | 0/5 | 0/8 | 0/11 | 0/11 | 0/1 | 0/4 | 1/16 | 0/4 | 1/3 | 0/6 | 1/36 | 0/13 | 0/22 | 0/1 | 0/4 | 0/14 | 3/255 | 1/44 | 0/23 | 0/4 | 0/6 | 0/5 | 0/1 | 0/1 | 0/19 | 0/42 | 0/2 | 0/1 | 0/1 |
| PneumoniaInfections and infestations | 0/1 | 0/1 | 0/2 | 1/7 | 1/24 | 0/25 | 0/15 | 4/27 | 0/7 | 0/39 | 4/115 | 0/59 | 1/5 | 0/5 | 0/5 | 0/8 | 1/11 | 1/11 | 0/1 | 0/4 | 0/16 | 0/4 | 1/3 | 0/6 | 1/36 | 0/13 | 1/22 | 0/1 | 0/4 | 0/14 | 13/255 | 1/44 | 0/23 | 0/4 | 0/6 | 0/5 | 0/1 | 0/1 | 1/19 | 0/42 | 0/2 | 0/1 | 0/1 |
| Cardiac aneurysmCardiac disorders | 0/1 | 0/1 | 0/2 | 0/7 | 0/24 | 0/25 | 0/15 | 0/27 | 0/7 | 0/39 | 0/115 | 0/59 | 0/5 | 0/5 | 0/5 | 0/8 | 0/11 | 0/11 | 0/1 | 0/4 | 0/16 | 0/4 | 0/3 | 0/6 | 0/36 | 0/13 | 0/22 | 0/1 | 1/4 | 0/14 | 0/255 | 0/44 | 0/23 | 0/4 | 0/6 | 0/5 | 0/1 | 0/1 | 0/19 | 0/42 | 0/2 | 0/1 | 0/1 |
| Atrial septal defectCongenital, familial and genetic disorders | 0/1 | 0/1 | 0/2 | 0/7 | 0/24 | 0/25 | 0/15 | 0/27 | 0/7 | 0/39 | 0/115 | 0/59 | 0/5 | 0/5 | 0/5 | 0/8 | 0/11 | 0/11 | 0/1 | 0/4 | 0/16 | 0/4 | 0/3 | 0/6 | 0/36 | 0/13 | 0/22 | 0/1 | 1/4 | 0/14 | 0/255 | 0/44 | 0/23 | 0/4 | 0/6 | 0/5 | 0/1 | 0/1 | 0/19 | 0/42 | 0/2 | 0/1 | 0/1 |
| Abdominal painGastrointestinal disorders | 0/1 | 0/1 | 0/2 | 0/7 | 0/24 | 2/25 | 0/15 | 0/27 | 0/7 | 0/39 | 2/115 | 0/59 | 0/5 | 0/5 | 0/5 | 0/8 | 0/11 | 0/11 | 0/1 | 0/4 | 0/16 | 1/4 | 0/3 | 0/6 | 0/36 | 0/13 | 1/22 | 0/1 | 0/4 | 0/14 | 2/255 | 0/44 | 0/23 | 0/4 | 0/6 | 0/5 | 0/1 | 0/1 | 0/19 | 1/42 | 0/2 | 0/1 | 0/1 |
| AscitesGastrointestinal disorders | 0/1 | 0/1 | 0/2 | 0/7 | 0/24 | 1/25 | 0/15 | 0/27 | 0/7 | 0/39 | 0/115 | 1/59 | 0/5 | 0/5 | 0/5 | 0/8 | 0/11 | 0/11 | 0/1 | 0/4 | 0/16 | 1/4 | 0/3 | 0/6 | 1/36 | 0/13 | 0/22 | 0/1 | 0/4 | 0/14 | 1/255 | 0/44 | 0/23 | 0/4 | 0/6 | 0/5 | 0/1 | 0/1 | 0/19 | 0/42 | 0/2 | 0/1 | 0/1 |
| DysphagiaGastrointestinal disorders | 0/1 | 0/1 | 0/2 | 0/7 | 0/24 | 0/25 | 0/15 | 0/27 | 0/7 | 0/39 | 1/115 | 0/59 | 0/5 | 0/5 | 0/5 | 0/8 | 0/11 | 0/11 | 0/1 | 1/4 | 0/16 | 0/4 | 0/3 | 1/6 | 0/36 | 0/13 | 0/22 | 0/1 | 0/4 | 0/14 | 1/255 | 0/44 | 0/23 | 0/4 | 1/6 | 0/5 | 0/1 | 0/1 | 0/19 | 1/42 | 0/2 | 0/1 | 0/1 |
| Event | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg | Crossover: Fela 0.100 mg/kg + Pembro 200 mg | Crossover: Fela 0.300 mg/kg + Pembro 200 mg | Crossover: Fela 1.000 mg/kg + Pembro 200 mg | Crossover: Fela 3.000 mg/kg + Pembro 200 mg | Crossover: Fela 24 mg + Pembro 200 mg | Crossover: Pembro 200 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 1/1 | 0/1 | 1/2 | 1/7 | 3/24 | 2/25 | 2/15 | 2/27 | 1/7 | 9/39 | 9/115 | 7/59 | 0/5 | 1/5 | 2/5 | 1/8 | 0/11 | 1/11 | 0/1 | 0/4 | 1/16 | 0/4 | 1/3 | 2/6 | 4/36 | 2/13 | 4/22 | 0/1 | 0/4 | 1/14 | 31/255 | 3/44 | 2/23 | 0/4 | 0/6 | 0/5 | 0/1 | 0/1 | 0/19 | 0/42 | 0/2 | 0/1 | 0/1 |
| DiarrhoeaGastrointestinal disorders | 1/1 | 0/1 | 1/2 | 0/7 | 2/24 | 2/25 | 3/15 | 3/27 | 0/7 | 6/39 | 21/115 | 9/59 | 0/5 | 1/5 | 1/5 | 1/8 | 2/11 | 2/11 | 0/1 | 1/4 | 2/16 | 1/4 | 1/3 | 1/6 | 12/36 | 1/13 | 7/22 | 0/1 | 1/4 | 0/14 | 46/255 | 7/44 | 8/23 | 1/4 | 1/6 | 0/5 | 0/1 | 0/1 | 2/19 | 0/42 | 0/2 | 0/1 | 0/1 |
| DyspepsiaGastrointestinal disorders | 0/1 | 1/1 | 0/2 | 0/7 | 1/24 | 0/25 | 1/15 | 0/27 | 0/7 | 0/39 | 0/115 | 0/59 | 0/5 | 0/5 | 0/5 | 0/8 | 0/11 | 0/11 | 0/1 | 0/4 | 0/16 | 0/4 | 0/3 | 0/6 | 0/36 | 1/13 | 0/22 | 0/1 | 0/4 | 0/14 | 0/255 | 0/44 | 0/23 | 0/4 | 0/6 | 0/5 | 0/1 | 0/1 | 1/19 | 1/42 | 0/2 | 0/1 | 0/1 |
| DysphagiaGastrointestinal disorders | 0/1 | 0/1 | 0/2 | 0/7 | 2/24 | 0/25 | 1/15 | 1/27 | 0/7 | 0/39 | 0/115 | 0/59 | 0/5 | 0/5 | 0/5 | 0/8 | 0/11 | 0/11 | 0/1 | 0/4 | 0/16 | 0/4 | 0/3 | 0/6 | 0/36 | 2/13 | 3/22 | 0/1 | 0/4 | 0/14 | 14/255 | 2/44 | 1/23 | 1/4 | 0/6 | 0/5 | 1/1 | 0/1 | 0/19 | 0/42 | 0/2 | 0/1 | 0/1 |
| Irritable bowel syndromeGastrointestinal disorders | 0/1 | 0/1 | 0/2 | 0/7 | 0/24 | 0/25 | 0/15 | 0/27 | 0/7 | 0/39 | 0/115 | 0/59 | 0/5 | 0/5 | 0/5 | 0/8 | 0/11 | 0/11 | 0/1 | 0/4 | 0/16 | 0/4 | 0/3 | 0/6 | 0/36 | 0/13 | 0/22 | 0/1 | 0/4 | 0/14 | 0/255 | 0/44 | 0/23 | 0/4 | 0/6 | 0/5 | 0/1 | 0/1 | 0/19 | 0/42 | 0/2 | 1/1 | 0/1 |
| NauseaGastrointestinal disorders | 0/1 | 0/1 | 2/2 | 0/7 | 3/24 | 1/25 | 3/15 | 6/27 | 0/7 | 8/39 | 24/115 | 9/59 | 3/5 | 2/5 | 3/5 | 1/8 | 2/11 | 1/11 | 0/1 | 0/4 | 1/16 | 0/4 | 1/3 | 5/6 | 20/36 | 5/13 | 11/22 | 0/1 | 1/4 | 2/14 | 46/255 | 7/44 | 3/23 | 0/4 | 0/6 | 0/5 | 1/1 | 0/1 | 1/19 | 7/42 | 0/2 | 0/1 | 0/1 |
| ProctalgiaGastrointestinal disorders | 1/1 | 0/1 | 0/2 | 0/7 | 0/24 | 0/25 | 0/15 | 0/27 | 0/7 | 0/39 | 0/115 | 0/59 | 0/5 | 0/5 | 0/5 | 0/8 | 0/11 | 0/11 | 0/1 | 0/4 | 0/16 | 1/4 | 0/3 | 0/6 | 0/36 | 0/13 | 0/22 | 0/1 | 0/4 | 0/14 | 0/255 | 0/44 | 0/23 | 0/4 | 0/6 | 0/5 | 0/1 | 0/1 | 0/19 | 0/42 | 0/2 | 0/1 | 0/1 |
| VomitingGastrointestinal disorders | 0/1 | 0/1 | 1/2 | 0/7 | 3/24 | 1/25 | 2/15 | 3/27 | 0/7 | 5/39 | 18/115 | 2/59 | 1/5 | 3/5 | 3/5 | 1/8 | 2/11 | 0/11 | 0/1 | 0/4 | 4/16 | 0/4 | 2/3 | 1/6 | 6/36 | 2/13 | 6/22 | 0/1 | 1/4 | 1/14 | 28/255 | 2/44 | 2/23 | 0/4 | 0/6 | 0/5 | 1/1 | 0/1 | 2/19 | 3/42 | 0/2 | 0/1 | 0/1 |
| AstheniaGeneral disorders | 0/1 | 0/1 | 0/2 | 1/7 | 5/24 | 2/25 | 1/15 | 4/27 | 2/7 | 11/39 | 27/115 | 15/59 | 0/5 | 1/5 | 0/5 | 0/8 | 0/11 | 2/11 | 0/1 | 1/4 | 3/16 | 1/4 | 1/3 | 3/6 | 10/36 | 2/13 | 1/22 | 0/1 | 0/4 | 1/14 | 48/255 | 10/44 | 4/23 | 1/4 | 1/6 | 0/5 | 1/1 | 0/1 | 5/19 | 5/42 | 0/2 | 1/1 | 0/1 |
| FatigueGeneral disorders | 0/1 | 1/1 | 0/2 | 2/7 | 5/24 | 4/25 | 3/15 | 6/27 | 0/7 | 5/39 | 20/115 | 9/59 | 1/5 | 1/5 | 5/5 | 2/8 | 1/11 | 0/11 | 0/1 | 3/4 | 1/16 | 0/4 | 1/3 | 0/6 | 8/36 | 4/13 | 10/22 | 0/1 | 2/4 | 1/14 | 46/255 | 8/44 | 4/23 | 0/4 | 1/6 | 0/5 | 0/1 | 0/1 | 0/19 | 3/42 | 0/2 | 0/1 | 0/1 |
| Age, Customized(Participants) | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18 - 93 years | 1 | 1 | 2 | 7 | 24 | 25 | 15 | 27 | 7 | 39 | 115 | 59 | 5 | 5 | 5 | 8 | 11 | 11 | 1 | 4 | 16 | 4 | 3 | 6 | 36 | 13 | 22 | 1 | 4 | 14 | 255 | 44 | 23 | 4 | 6 | 5 | 1 | 829 |
| Sex: Female, Male(Participants) | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 0 | 1 | 4 | 11 | 14 | 4 | 11 | 2 | 18 | 47 | 25 | 1 | 2 | 2 | 3 | 4 | 5 | 0 | 1 | 8 | 0 | 3 | 1 | 13 | 1 | 5 | 0 | 0 | 2 | 115 | 15 | 4 | 0 | 0 | 2 | 0 | 325 |
| Male | 0 | 1 | 1 | 3 | 13 | 11 | 11 | 16 | 5 | 21 | 68 | 34 | 4 | 3 | 3 | 5 | 7 | 6 | 1 | 3 | 8 | 4 | 0 | 5 | 23 | 12 | 17 | 1 | 4 | 12 | 140 | 29 | 19 | 4 | 6 | 3 | 1 | 504 |
| Race/Ethnicity, Customized(Participants) | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HISPANIC OR LATINO | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 4 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 1 | 8 | 1 | 1 | 1 | 0 | 0 | 1 | 33 |
| NOT HISPANIC OR LATINO | 1 | 1 | 2 | 7 | 22 | 22 | 14 | 23 | 7 | 33 | 98 | 55 | 4 | 4 | 5 | 8 | 10 | 11 | 0 | 3 | 15 | 3 | 2 | 5 | 34 | 11 | 21 | 1 | 4 | 11 | 226 | 39 | 15 | 3 | 5 | 5 | 0 | 730 |
| Missing | 0 | 0 | 0 | 0 | 2 | 3 | 1 | 3 | 0 | 4 | 13 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 2 | 21 | 4 | 7 | 0 | 1 | 0 | 0 | 66 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jun 2016 to primary completion in Jul 2023, 84 months.
Results were first posted in Dec 2024, 1 year 5 months after primary completion.
Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 84 months is above that.
Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Feladilimab